[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 119
1. Zielinski GD, Snijders PJ, Rozendaal L, Daalmeijer NF, Risse EK, Voorhorst FJ, Jiwa NM, van der Linden HC, de Schipper FA, Runsink AP, Meijer CJ: The presence of high-risk HPV combined with specific p53 and p16INK4a expression patterns points to high-risk HPV as the main causative agent for adenocarcinoma in situ and adenocarcinoma of the cervix. J Pathol; 2003 Dec;201(4):535-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The presence of high-risk HPV combined with specific p53 and p16INK4a expression patterns points to high-risk HPV as the main causative agent for adenocarcinoma in situ and adenocarcinoma of the cervix.
  • Adenocarcinoma in situ (ACIS) and adenocarcinoma (AdCA) of the cervix are frequently missed in population-based screening programmes.
  • Adding high-risk HPV (hrHPV) testing to cervical cancer screening might improve the detection rate of ACIS and AdCA.
  • Since the exact proportion of AdCAs of the cervix that can be attributed to hrHPV infection is still a matter of debate, a comprehensive study was performed of hrHPV presence in ACIS and AdCA of the cervix.
  • Archival formalin-fixed specimens of indisputable ACIS (n=65) and AdCA (n=77) of the cervix were tested for hrHPV DNA by GP5+/6+ PCR-enzyme immunoassay (EIA) and type-specific E7 PCR for 14 hrHPV types.
  • Further immunostaining for p16INK4A and p53 was performed to assess alternative pathways of carcinogenesis potentially unrelated to HPV. hrHPV DNA was found in all (100%) ACISs and 72 (94%) cervical AdCAs, whereas none of 20 endometrial AdCAs scored hrHPV-positive.
  • HPV 18 was most prevalent and found as single or multiple infection in 68% of ACISs and 55% of cervical AdCAs.
  • Diffuse immunostaining for p16INK4a, a potential marker of hrHPV E7 function, was significantly more frequent in hrHPV-positive cervical AdCAs (19/20; 95%) than in those without hrHPV (1/5; 20%; p<0.001).
  • Immunostaining for p53, pointing to stabilized wild-type or mutant p53 protein, was significantly more frequent in hrHPV cervical AdCAs negative for hrHPV (p=0.01).
  • No difference in p16INK4a and p53 immunostaining was found between hrHPV-negative cervical AdCAs and endometrial AdCAs.
  • Hence, only a minority of cervical AdCAs displayed absence of HPV DNA and immunostaining profiles suggestive of an aetiology independent of HPV.
  • Since all ACISs and nearly all cervical AdCAs were hrHPV-positive, the incorporation of hrHPV testing in cervical cancer screening programmes is likely to decrease markedly the incidence of cervical AdCA.
  • [MeSH-major] Adenocarcinoma / etiology. Carcinoma in Situ / etiology. Papillomaviridae / genetics. Papillomavirus Infections / complications. Uterine Cervical Neoplasms / etiology


2. Barz M, Wolf FK, Canal F, Koynov K, Vicent MJ, Frey H, Zentel R: Synthesis, Characterization and Preliminary Biological Evaluation of P(HPMA)-b-P(LLA) Copolymers: A New Type of Functional Biocompatible Block Copolymer. Macromol Rapid Commun; 2010 Sep 1;31(17):1492-500
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synthesis, Characterization and Preliminary Biological Evaluation of P(HPMA)-b-P(LLA) Copolymers: A New Type of Functional Biocompatible Block Copolymer.
  • The synthesis relies on a combination of ring-opening polymerization of L-lactide, conversion into a chain transfer agent (CTA) for the RAFT polymerization of pentafluorophenyl methacrylate.
  • The fluorescence label attached to this new type of a partially degradable amphiphilic block copolymer was used to study cellular uptake in human cervix adenocarcinoma (HeLa) cells as well as aggregation behavior by fluorescence correlation spectroscopy (FCS).

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
  • (PMID = 21567557.001).
  • [ISSN] 1521-3927
  • [Journal-full-title] Macromolecular rapid communications
  • [ISO-abbreviation] Macromol Rapid Commun
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


3. Yokoyama M, Noguchi M, Nakao Y, Ysunaga M, Yamasaki F, Iwasaka T: Antiproliferative effects of the major tea polyphenol, (-)-epigallocatechin gallate and retinoic acid in cervical adenocarcinoma. Gynecol Oncol; 2008 Feb;108(2):326-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antiproliferative effects of the major tea polyphenol, (-)-epigallocatechin gallate and retinoic acid in cervical adenocarcinoma.
  • OBJECTIVE: To investigate the combined effect of the major tea polyphenol, (-)-epigallocatechin gallate (EGCG) and retinoic acid (RA) on cervical adenocarcinoma.
  • METHODS: Cell growth rate was examined after treatment for 4, 7 and 10 days with 0-100 microM EGCG and/or 1 microM RA in two cervical adenocarcinoma cell lines, HeLa and TMCC-1.
  • RESULTS: Combining EGCG and RA increased the antiproliferative effect in adenocarcinoma cell lines, whereas EGCG or RA treatment alone caused a less sensitive response in these cells.
  • The combination treatment of EGCG and RA induced apoptosis and inhibited telomerase activity in adenocarcinoma cell lines.
  • These results were consistent with those of an antiproliferative effect of EGCG and/or RA in cervical adenocarcinoma cells.
  • CONCLUSION: Our data suggest that EGCG and RA combined to prevent the carcinogenesis of cervical adenocarcinoma, induce apoptosis and inhibit telomerase activity.
  • The treatments of combining EGCG and RA may be effective in preventing or treating cervical adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / pharmacology. Catechin / analogs & derivatives. Tretinoin / pharmacology. Uterine Cervical Neoplasms / drug therapy
  • [MeSH-minor] Apoptosis / drug effects. Caspase 3 / metabolism. Cell Growth Processes / drug effects. Cell Line, Tumor. Dose-Response Relationship, Drug. Drug Synergism. Female. HeLa Cells. Humans. Telomerase / metabolism

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18035403.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 5688UTC01R / Tretinoin; 8R1V1STN48 / Catechin; BQM438CTEL / epigallocatechin gallate; EC 2.7.7.49 / TERT protein, human; EC 2.7.7.49 / Telomerase; EC 3.4.22.- / Caspase 3
  •  go-up   go-down


Advertisement
4. Han M, Chen JL, Hu Y, He CL, Shuai WP, Yu JH, Chen HL, Liang WQ, Mayumi T, Shinsaku N, Gao JQ: In vitro and in vivo tumor suppressive activity induced by human telomerase transcriptase-targeting antisense oligonucleotides mediated by cationic liposomes. J Biosci Bioeng; 2008 Sep;106(3):243-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The objective of this study was to investigate the in vitro and in vivo influence of cationic liposomes on the tumor suppressive effect of antisense telomerase oligodeoxynucleotides to human cervical adenocarcinoma cells (HeLa).
  • [MeSH-major] Cell Survival / genetics. Drug Carriers / chemistry. Liposomes / chemistry. Oligonucleotides, Antisense / administration & dosage. Oligonucleotides, Antisense / genetics. Telomerase / genetics. Transfection / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18929999.001).
  • [ISSN] 1347-4421
  • [Journal-full-title] Journal of bioscience and bioengineering
  • [ISO-abbreviation] J. Biosci. Bioeng.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Cations; 0 / Drug Carriers; 0 / Liposomes; 0 / Oligonucleotides, Antisense; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


5. Lui M, Boerner S: Arias-Stella reaction in a cervicovaginal smear of a woman undergoing infertility treatment: a case report. Diagn Cytopathol; 2005 Feb;32(2):94-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although the cytological diagnoses of Arias-Stella reaction by cervical Papanicolaou (Pap) smears in pregnant, postpartum, and postabortal women are documented, to our knowledge, this is the first report of Arias-Stella reaction in a cervicovaginal smear of a nonpregnant woman undergoing infertility treatment with clomiphene and beta-human chorionic gonadotropin (beta-HCG).
  • It is of paramount importance to recognize this phenomenon in cervical Pap smears, especially in women receiving ovulation-inducing agents and exogenous hormonal treatment to avoid this potential cytological pitfall.
  • [MeSH-major] Cervix Uteri / cytology. Infertility, Female. Papanicolaou Test. Vaginal Smears
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / pathology. Adult. False Positive Reactions. Female. Fertility Agents, Female / therapeutic use. Glucosides. Humans. Uterine Cervical Neoplasms / diagnosis. Uterine Cervical Neoplasms / pathology


6. Vukovic V, Nicklee T, Hedley DW: Microregional heterogeneity of non-protein thiols in cervical carcinomas assessed by combined use of HPLC and fluorescence image analysis. Clin Cancer Res; 2000 May;6(5):1826-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microregional heterogeneity of non-protein thiols in cervical carcinomas assessed by combined use of HPLC and fluorescence image analysis.
  • Intra- and intertumoral heterogeneity of glutathione (GSH) and cysteine were assessed in cryostat sections of multiple biopsies obtained from 10 cervical carcinomas by the combined use of a sensitive high-performance liquid chromatography (HPLC) method and a fluorescence image analysis technique to examine the spatial distribution of NPSHs in tumor tissue.
  • Because some cervical carcinomas contain radiobiologically important levels of cysteine, agents that target the biochemical pathways maintaining tumor cysteine have therapeutic potential as adjuncts to radiotherapy in cervix cancer patients.
  • [MeSH-major] Adenocarcinoma / metabolism. Carcinoma, Squamous Cell / metabolism. Cysteine / analysis. Glutathione / analysis. Uterine Cervical Neoplasms / metabolism
  • [MeSH-minor] Cervix Uteri / chemistry. Cervix Uteri / pathology. Chromatography, High Pressure Liquid. Female. Humans. Image Processing, Computer-Assisted. Microscopy, Fluorescence

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • Hazardous Substances Data Bank. CYSTEINE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10815904.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] GAN16C9B8O / Glutathione; K848JZ4886 / Cysteine
  •  go-up   go-down


7. Yeasmin S, Nakayama K, Ishibashi M, Katagiri A, Iida K, Purwana IN, Nakayama N, Miyazaki K: Expression of the bric-a-brac tramtrack broad complex protein NAC-1 in cervical carcinomas seems to correlate with poorer prognosis. Clin Cancer Res; 2008 Mar 15;14(6):1686-91
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of the bric-a-brac tramtrack broad complex protein NAC-1 in cervical carcinomas seems to correlate with poorer prognosis.
  • The aim of this study was to clarify the functional role of NAC-1 in human cervical carcinomas.
  • EXPERIMENTAL DESIGN: NAC-1 expression in cervical cancer was assessed by immunohistochemistry, and data on clinical variables were collected by retrospective chart review.
  • NAC-1 gene knockdown using small interfering RNA and a NAC-1 gene transfection system were used to asses NAC-1 function in cervical cancer in vivo.
  • RESULTS: Immunohistochemical and gene expression analysis revealed that NAC-1 is significantly overexpressed in cervical adenocarcinomas and adenosquamous carcinomas compared with squamous cell carcinomas.
  • Overexpressions of the NAC-1 gene stimulated cell proliferation in cervical carcinoma cells of the TCS, CaSki, and HeLa P3 lines, which do not have endogenous NAC-1 expression.
  • CONCLUSIONS: Our findings suggest that NAC-1 may play an important role in cervical carcinomas; moreover, these findings provide a rationale for future development of NAC-1-based therapy for cervical carcinomas that overexpress this candidate oncogene.
  • [MeSH-major] Adenocarcinoma / diagnosis. Neoplasm Proteins / metabolism. Repressor Proteins / metabolism. Uterine Cervical Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Apoptosis / drug effects. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / radiotherapy. Female. Gene Expression Regulation, Neoplastic. HeLa Cells. Humans. Middle Aged. Multiprotein Complexes / genetics. Multiprotein Complexes / metabolism. Prognosis. RNA, Small Interfering / pharmacology. Survival Analysis. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18347169.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Multiprotein Complexes; 0 / NACC1 protein, human; 0 / Neoplasm Proteins; 0 / RNA, Small Interfering; 0 / Repressor Proteins
  •  go-up   go-down


8. Baba T, Koizumi M, Suzuki T, Yamanaka I, Yamashita S, Kudo R: Cloning and characterization of a tumor-associated antigen, beta-casein-like protein. Biochem Biophys Res Commun; 2001 Jun 8;284(2):340-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Monoclonal antibody (MAb) 1C5 reacts with 87% of uterine cervical adenocarcinoma and bovine beta -casein, but not with squamous cell carcinoma.
  • The protein predicted from the cDNA consisting of 937 nucleotides comprises 222 amino acids.
  • The BCLP gene and deduced amino acid sequences were novel and showed no similarity to known cancer-associated genes in the database.
  • Northern blot analysis showed that a 1.1 kb transcript was ubiquitously expressed in cancer cell lines and was predominantly expressed in uterine cervical adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / metabolism. Antigens, Neoplasm / genetics. Antigens, Neoplasm / metabolism. Caseins / genetics. Caseins / metabolism. Uterine Neoplasms / metabolism
  • [MeSH-minor] Amino Acid Sequence. Antibodies, Monoclonal / metabolism. Base Sequence. Blotting, Northern. Cell Adhesion / drug effects. Cell Division / drug effects. Cell Size / drug effects. Cloning, Molecular. DNA, Complementary / genetics. DNA, Complementary / isolation & purification. DNA, Complementary / pharmacology. Down-Regulation / drug effects. Female. Fibroblasts / cytology. Fibroblasts / drug effects. Fibroblasts / metabolism. Humans. Molecular Sequence Data. RNA, Messenger / metabolism. Transfection. Tumor Cells, Cultured. Uterine Cervical Neoplasms / metabolism. Uterine Cervical Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 Academic Press.
  • (PMID = 11394883.001).
  • [ISSN] 0006-291X
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, Neoplasm; 0 / Caseins; 0 / DNA, Complementary; 0 / RNA, Messenger; 0 / TMEM54 protein, human
  •  go-up   go-down


9. Kim HG, Song H, Yoon DH, Song BW, Park SM, Sung GH, Cho JY, Park HI, Choi S, Song WO, Hwang KC, Kim TW: Cordyceps pruinosa extracts induce apoptosis of HeLa cells by a caspase dependent pathway. J Ethnopharmacol; 2010 Mar 24;128(2):342-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIM OF THE STUDY: Cordyceps is a parasitic fungus and has long been used as a traditional Chinese medicine to treat illnesses, promote longevity, increase athletic power, and relieve exhaustion and cancer.
  • In this study, we reveal the mechanisms underlying apoptosis induced by Cordyceps pruinosa butanol fraction (CPBF) in the human cervical adenocarcinoma cell line, HeLa.
  • CONCLUSIONS: These results indicate that apoptotic effects of CPBF on HeLa cells are mediated by mitochondria-dependent death-signaling pathway independent of reactive oxygen species, suggesting that CPBF might be effective as an anti-proliferative agent for cancer.
  • [MeSH-major] Apoptosis / drug effects. Caspase 3 / metabolism. Caspases / metabolism. Cordyceps / metabolism. Plant Extracts / pharmacology
  • [MeSH-minor] Cytochrome c Group / metabolism. Cytochromes c / metabolism. DNA Fragmentation / drug effects. HeLa Cells. Humans. Mitochondria / metabolism. Poly(ADP-ribose) Polymerases / metabolism. Reactive Oxygen Species / metabolism. Signal Transduction / drug effects. bcl-2-Associated X Protein / metabolism

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 20138133.001).
  • [ISSN] 1872-7573
  • [Journal-full-title] Journal of ethnopharmacology
  • [ISO-abbreviation] J Ethnopharmacol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Cytochrome c Group; 0 / Plant Extracts; 0 / Reactive Oxygen Species; 0 / bcl-2-Associated X Protein; 116110-46-4 / cytochrome c''; 9007-43-6 / Cytochromes c; EC 2.4.2.30 / Poly(ADP-ribose) Polymerases; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspases
  •  go-up   go-down


10. Piura B, Rabinovich A, Aizenberg N, Wolfson M: [Cadherins in malignancies of the female genital tract]. Harefuah; 2005 Apr;144(4):261-5, 303, 302
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The three amino acids sequence, histidine, alanine and valine (HAV motif) located at the most external domain of the extracellular portion, plays a key role in homophilic recognition between two cadherin molecules and cell-cell adhesion.
  • Research of cadherin in malignancies has attracted much attention since cadherins may be proven to be reliable markers of biological behavior and prognosis The studies on cadherin in malignancies of the female genital tract have shown the following results:.
  • 2) In advanced-stage epithelial ovarian carcinoma (Stages II-IV) the results are at odds: some investigators have shown a loss of E-cadherin expression most often because of hypermethylation of the promoter region of the gene, while others have demonstrated an increase in E-cadherin expression;.
  • 3) In endometrial carcinoma, E-cadherin expression is decreasing and P-cadherin expression is increasing with worsening of histologic type and differentiation, increased penetration into the myometrium, spread beyond the uterus and involvement of pelvic lymph nodes;.
  • 4) In squamous cell carcinoma of the uterine cervix E-cadherin expression is decreasing with tumor progression and in adenocarcinoma of the uterine cervix P-cadherin expression is increasing with tumor progression.
  • It is hoped that the development of drugs that amend cell-cell adhesion will improve the prognosis of patients in whom tumor progression is associated with decrease or loss of cadherin expression.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15889610.001).
  • [ISSN] 0017-7768
  • [Journal-full-title] Harefuah
  • [ISO-abbreviation] Harefuah
  • [Language] heb
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Israel
  • [Chemical-registry-number] 0 / Cadherins
  • [Number-of-references] 38
  •  go-up   go-down


11. Agrawal M, Edgerly M, Fojo T, Kotz H: Treatment of recurrent cervical adenocarcinoma with BMS-247550, an epothilone B analog. Gynecol Oncol; 2003 Jul;90(1):96-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of recurrent cervical adenocarcinoma with BMS-247550, an epothilone B analog.
  • OBJECTIVE: The incidence of recurrent cervical adenocarcinoma is rising relative to the squamous subtype.
  • There are limited therapeutic options for women with advanced cervical adenocarcinoma.
  • Only a few chemotherapy agents have demonstrated activity in this disease.
  • This report describes results with BMS-247550, an epothilone B analog that stabilizes microtubules, with activity in previously treated adenocarcinoma of the cervix.
  • METHOD: We present two women with recurrent cervical adenocarcinoma with metastases to the lung.
  • The ultimate role of BMS-247550 and multiagent chemotherapy in the treatment of adenocarcinoma of the cervix should be further investigated.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents / therapeutic use. Epothilones / therapeutic use. Neoplasm Recurrence, Local / drug therapy. Uterine Cervical Neoplasms / drug therapy


12. Treffers PE, Hanselaar AG, Helmerhorst TJ, Koster ME, van Leeuwen FE: [Consequences of diethylstilbestrol during pregnancy; 50 years later still a significant problem]. Ned Tijdschr Geneeskd; 2001 Apr 7;145(14):675-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Consequences of diethylstilbestrol during pregnancy; 50 years later still a significant problem].
  • [Transliterated title] Gevolgen van diëthylstilbestrol in de zwangerschap: na 50 jaar nog steeds een actueel probleem.
  • The most important consequences described are: for DES mothers an increased risk of mammary carcinomas and for DES daughters a 1 in 1000 chance of clear cell adenocarcinoma (CCAC) as well as an increased risk of (pre)malignant abnormalities of the stratified epithelium in the vagina and cervix.
  • In addition to this, DES daughters frequently have developmental disorders of the cervix and corpus uteri.
  • The DES problem continues to be an important issue.
  • The incidence of CCAC of the vagina and cervix in the population is bimodal, with a second peak at older age.
  • The legally imposed destruction of patient files after a period of ten years is a serious threat to patient care and scientific investigation, notably in obstetrics and child medicine.
  • [MeSH-major] Adenocarcinoma, Clear Cell / epidemiology. Breast Neoplasms / epidemiology. Carcinogens / adverse effects. Diethylstilbestrol / adverse effects. Genital Neoplasms, Female / epidemiology. Genitalia / abnormalities. Medical Records / legislation & jurisprudence. Pregnancy Complications / epidemiology
  • [MeSH-minor] Adult. Animals. Female. Genital Diseases, Female / epidemiology. Humans. Incidence. Male. Mice. Middle Aged. Netherlands / epidemiology. Pregnancy. Prenatal Exposure Delayed Effects

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Health Problems in Pregnancy.
  • Hazardous Substances Data Bank. DIETHYLSTILBESTROL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11530703.001).
  • [ISSN] 0028-2162
  • [Journal-full-title] Nederlands tijdschrift voor geneeskunde
  • [ISO-abbreviation] Ned Tijdschr Geneeskd
  • [Language] dut
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Carcinogens; 731DCA35BT / Diethylstilbestrol
  • [Number-of-references] 60
  •  go-up   go-down


13. Papoutsi Z, Kassi E, Papaevangeliou D, Pratsinis H, Zoumpourlis V, Halabalaki M, Mitakou S, Kalofoutis A, Moutsatsou P: Plant 2-arylobenzofurans demonstrate a selective estrogen receptor modulator profile. Steroids; 2004 Oct-Nov;69(11-12):727-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We examined their ability, (1) to induce the insulin growth factor binding protein-3 (IGFBP-3) in MCF-7 breast cancer cells, (2) to stimulate differentiation and mineralization of osteoblastic cell culture by histochemical staining for alkaline phosphatase, Alizarin Red-S staining and calcium levels in the supernatants and (3) to inhibit cell proliferation of cervical adenocarcinoma (Hela) cells by use of the MTT assay.
  • Our data reveal that ebenfuran II is a highly potent SERM, exhibiting antiestrogenic activity in breast cancer cells via the estrogen receptor, estrogenic effect on osteoblasts and no stimulatory effect on cervix adenocarcinoma cells.
  • In conclusion, our study is the first to demonstrate that plant derived arylobenzofurans show a SERM profile and may be considered for the prevention and treatment of diseases such as breast cancer, cervical cancer and osteoporosis.
  • [MeSH-major] Benzofurans / chemistry. Estradiol / analogs & derivatives. Estrogen Receptor Modulators / metabolism. Plants / metabolism. Plants, Medicinal
  • [MeSH-minor] Adenocarcinoma / metabolism. Alkaline Phosphatase / metabolism. Animals. Anthraquinones / pharmacology. Calcium / metabolism. Cell Differentiation. Cell Line. Cell Line, Tumor. Chloramphenicol O-Acetyltransferase / metabolism. Dose-Response Relationship, Drug. Estrogens / metabolism. Female. Furans / chemistry. HeLa Cells. Humans. Insulin-Like Growth Factor Binding Protein 3 / metabolism. Mice. Osteoblasts / metabolism. Receptors, Estrogen / metabolism. Tetrazolium Salts / pharmacology. Thiazoles / pharmacology. Time Factors. Transfection. Uterine Cervical Neoplasms / drug therapy

  • Hazardous Substances Data Bank. FULVESTRANT .
  • Hazardous Substances Data Bank. METHYLTHIAZOLETETRAZOLIUM .
  • Hazardous Substances Data Bank. ESTRADIOL .
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15579325.001).
  • [ISSN] 0039-128X
  • [Journal-full-title] Steroids
  • [ISO-abbreviation] Steroids
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anthraquinones; 0 / Benzofurans; 0 / Estrogen Receptor Modulators; 0 / Estrogens; 0 / Furans; 0 / Insulin-Like Growth Factor Binding Protein 3; 0 / Receptors, Estrogen; 0 / Tetrazolium Salts; 0 / Thiazoles; 22X328QOC4 / fulvestrant; 298-93-1 / thiazolyl blue; 3F3AT0Q12H / Alizarin Red S; 4TI98Z838E / Estradiol; EC 2.3.1.28 / Chloramphenicol O-Acetyltransferase; EC 3.1.3.1 / Alkaline Phosphatase; SY7Q814VUP / Calcium
  •  go-up   go-down


14. Synold TW, Takimoto CH, Doroshow JH, Gandara D, Mani S, Remick SC, Mulkerin DL, Hamilton A, Sharma S, Ramanathan RK, Lenz HJ, Graham M, Longmate J, Kaufman BM, Ivy P, National Cancer Institute Organ Dysfunction Working Group: Dose-escalating and pharmacologic study of oxaliplatin in adult cancer patients with impaired hepatic function: a National Cancer Institute Organ Dysfunction Working Group study. Clin Cancer Res; 2007 Jun 15;13(12):3660-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dose-escalating and pharmacologic study of oxaliplatin in adult cancer patients with impaired hepatic function: a National Cancer Institute Organ Dysfunction Working Group study.
  • EXPERIMENTAL DESIGN: Sixty adult cancer patients with variable hepatic function received i.v. oxaliplatin ranging from 60 to 130 mg/m(2) every 3 weeks.
  • RESULTS: Dose escalation of single-agent oxaliplatin to 130 mg/m(2) was well tolerated in all cohorts.
  • Two of 56 assessable patients with a diagnosis of laryngeal carcinoma and cervical adenocarcinoma experienced partial responses lasting 3 and 5.5 months.
  • Dose reductions of single-agent oxaliplatin are not indicated in patients with hepatic dysfunction.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Liver Diseases.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17575231.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01CA062502; United States / NCI NIH HHS / CA / U01CA069855; United States / NCI NIH HHS / CA / U01CA03330; United States / NCI NIH HHS / CA / U01CA076642; United States / NCRR NIH HHS / RR / M01RR00080; United States / NCI NIH HHS / CA / U01CA033572; United States / NCRR NIH HHS / RR / RR00056; United States / NCI NIH HHS / CA / U01CA069853; United States / NCI NIH HHS / CA / U01CA069856; United States / NCI NIH HHS / CA / U01 CA062491; United States / NCI NIH HHS / CA / U01CA062505; United States / NCI NIH HHS / CA / U01CA062491
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin
  •  go-up   go-down


15. Chung KS, Choi JH, Back NI, Choi MS, Kang EK, Chung HG, Jeong TS, Lee KT: Eupafolin, a flavonoid isolated from Artemisia princeps, induced apoptosis in human cervical adenocarcinoma HeLa cells. Mol Nutr Food Res; 2010 Sep;54(9):1318-28
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Eupafolin, a flavonoid isolated from Artemisia princeps, induced apoptosis in human cervical adenocarcinoma HeLa cells.
  • Although eupafolin, a flavone found in Artemisia princeps Pampanini, has been shown to inhibit the growth of several human cancer cells, its mode of action is poorly understood.
  • In this study, we investigated the pro-apoptotic activities of eupafolin in human cervical carcinoma HeLa cells.
  • Furthermore, treatment with eupafolin resulted in a loss of mitochondrial membrane potential (DeltaPsi(m)), increased the release of cytochrome c to the cytosol, and altered the expression levels of B-cell lymphoma 2 (Bcl-2) family proteins.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents, Phytogenic / pharmacology. Apoptosis / drug effects. Artemisia / chemistry. Flavones / pharmacology. Uterine Cervical Neoplasms / drug therapy
  • [MeSH-minor] Caspases / metabolism. Cell Line, Tumor. DNA Fragmentation / drug effects. Down-Regulation / drug effects. Enzyme Activation / drug effects. Female. HeLa Cells. Humans. Inhibitory Concentration 50. Kinetics. Membrane Potential, Mitochondrial / drug effects. Mitochondria / drug effects. Mitochondria / enzymology. Permeability / drug effects. Proto-Oncogene Proteins c-bcl-2 / genetics. Proto-Oncogene Proteins c-bcl-2 / metabolism

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20397191.001).
  • [ISSN] 1613-4133
  • [Journal-full-title] Molecular nutrition & food research
  • [ISO-abbreviation] Mol Nutr Food Res
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Flavones; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / eupafolin; EC 3.4.22.- / Caspases
  •  go-up   go-down


16. Saczko J, Skrzypek W, Chwiłkowska A, Choromańska A, Poła A, Gamian A, Kulbacka J: Photo-oxidative action in cervix carcinoma cells induced by HPD - mediated photodynamic therapy. Exp Oncol; 2009 Dec;31(4):195-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photo-oxidative action in cervix carcinoma cells induced by HPD - mediated photodynamic therapy.
  • Oxidative stress causes damage to cellular macromolecules such as nucleic acids, proteins and lipids.
  • AIM: To examine the hematoporphyrin derivative (HpD) - mediated photodynamic effect on cervical adenocarcinoma cell line HeLa.
  • HpD-PDT might be alternative and less invasive approach for treatment of patients with cervical cancer resistant for standard chemotherapy and radiotherapy.
  • [MeSH-major] Adenocarcinoma / therapy. Hematoporphyrin Derivative / pharmacology. Photochemotherapy / methods. Uterine Cervical Neoplasms / therapy
  • [MeSH-minor] Female. HeLa Cells. Humans. Immunohistochemistry. Lipid Peroxidation / drug effects. Microscopy, Confocal. Nitric Oxide Synthase Type II / drug effects. Nitric Oxide Synthase Type II / metabolism. Oxidative Stress / drug effects. Superoxide Dismutase / drug effects. Superoxide Dismutase / metabolism

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20010535.001).
  • [ISSN] 1812-9269
  • [Journal-full-title] Experimental oncology
  • [ISO-abbreviation] Exp. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ukraine
  • [Chemical-registry-number] 68335-15-9 / Hematoporphyrin Derivative; EC 1.14.13.39 / Nitric Oxide Synthase Type II; EC 1.15.1.1 / Superoxide Dismutase
  •  go-up   go-down


17. Florea AM, Splettstoesser F, Dopp E, Rettenmeier AW, Büsselberg D: Modulation of intracellular calcium homeostasis by trimethyltin chloride in human tumour cells: neuroblastoma SY5Y and cervix adenocarcinoma HeLa S3. Toxicology; 2005 Dec;216(1):1-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Modulation of intracellular calcium homeostasis by trimethyltin chloride in human tumour cells: neuroblastoma SY5Y and cervix adenocarcinoma HeLa S3.
  • TMT) modulates calcium homeostasis in cervix adenocarcinoma (HeLa S3) cells [Florea, A.
  • [MeSH-major] Calcium / metabolism. Calcium Signaling / drug effects. Homeostasis / drug effects. Intracellular Space / metabolism. Trimethyltin Compounds / toxicity
  • [MeSH-minor] Adenocarcinoma / metabolism. Cell Line, Tumor. Dose-Response Relationship, Drug. Fluorescent Dyes. Humans. Microscopy, Confocal. Neuroblastoma / metabolism

  • Genetic Alliance. consumer health - Neuroblastoma.
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16125831.001).
  • [ISSN] 0300-483X
  • [Journal-full-title] Toxicology
  • [ISO-abbreviation] Toxicology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Fluorescent Dyes; 0 / Trimethyltin Compounds; 1631-73-8 / trimethyltin; SY7Q814VUP / Calcium
  •  go-up   go-down


18. Gomez-Monterrey I, Campiglia P, Carotenuto A, Stiuso P, Bertamino A, Sala M, Aquino C, Grieco P, Morello S, Pinto A, Ianelli P, Novellino E: Spiro[(dihydropyrazin-2,5-dione)-6,3'-(2',3'-dihydrothieno[2,3-b]naphtho-4',9'-dione)]-based cytotoxic agents: structure-activity relationship studies on the substituent at N4-position of the diketopiperazine domain. J Med Chem; 2008 May 22;51(10):2924-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spiro[(dihydropyrazin-2,5-dione)-6,3'-(2',3'-dihydrothieno[2,3-b]naphtho-4',9'-dione)]-based cytotoxic agents: structure-activity relationship studies on the substituent at N4-position of the diketopiperazine domain.
  • These compounds, in both racemic and pure enantiomeric forms, showed also a high efficacy in cell lines resistant to doxorubicin (MCF-7/Dx) and in cell lines that were highly resistant to treatment with doxorubicin, such as HEK-293 (kidney), M-14 (melanoma), and HeLa (cervical adenocarcinoma) human cell lines.
  • In addition, the effects on growth and cell cycle progression in CaCo-2 cell line (colon adenocarcinoma) and DNA-binding properties were investigated.
  • [MeSH-major] Antineoplastic Agents / chemical synthesis. Diketopiperazines / chemical synthesis. Naphthoquinones / chemical synthesis. Pyrazines / chemical synthesis
  • [MeSH-minor] Cell Cycle / drug effects. Cell Line, Tumor. DNA / chemistry. Drug Screening Assays, Antitumor. Humans. Magnetic Resonance Spectroscopy. Models, Molecular. Structure-Activity Relationship

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18429610.001).
  • [ISSN] 0022-2623
  • [Journal-full-title] Journal of medicinal chemistry
  • [ISO-abbreviation] J. Med. Chem.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 4-((2-N,N-dimethyl)amino)ethylspiro((dihydropyrazin-2,5-dione)-6,3'-(2',3'-dihydrothieno(2,3-b)naphtho-4',9'-dione)); 0 / 4-(2-pyrrolidine)ethylspiro((dihydropyrazin-2,5-dione)-6,3'-(2',3'-dihydrothieno(2,3-b)naphtho-4',9'-dione)); 0 / Antineoplastic Agents; 0 / Diketopiperazines; 0 / Naphthoquinones; 0 / Pyrazines; 9007-49-2 / DNA
  •  go-up   go-down


19. Hatae M, Kanda E, Nakamura T, Yamamoto F, Ohnishi Y: [Chemotherapy for cervical carcinoma]. Gan To Kagaku Ryoho; 2005 Aug;32(8):1104-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Chemotherapy for cervical carcinoma].
  • Although cisplatin-based chemotherapy is standard regime for cervical cancer, the major question remains as to what kind of drug is the best candidate for combination with cisplatin.
  • According to recent reports, platinum+taxane is supposed to be a promising combination for not only squamous cell carcinoma but also adenocarcinoma of cervix.
  • Studies of neoadjuvant chemotherapy followed by radiotherapy demonstrate no advantage for overall survival of locally advanced cervical carcinoma.
  • Concurrent radiotherapy with weekly cisplatin is standard therapy for primary and adjuvant setting for squamous cell carcinoma and adenocarcinoma of cervix.
  • [MeSH-major] Uterine Cervical Neoplasms / drug therapy
  • [MeSH-minor] Drug Therapy, Combination. Female. Humans. Neoadjuvant Therapy

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16121910.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 26
  •  go-up   go-down


20. Yang YC, Lee ZY, Wu CC, Chen TC, Chang CL, Chen CP: CXCR4 expression is associated with pelvic lymph node metastasis in cervical adenocarcinoma. Int J Gynecol Cancer; 2007 May-Jun;17(3):676-86
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CXCR4 expression is associated with pelvic lymph node metastasis in cervical adenocarcinoma.
  • The aim of this study is to investigate the expression of CXCR4 receptor in cervical adenocarcinoma and related mechanisms involved in pelvic lymph node metastasis.
  • Immunohistochemistry was used to evaluate the expression of CXCR4 and the association of pelvic lymph node metastasis in archived tissue from clinical stage IB cervical adenocarcinomas (n = 37) and from benign specimens obtained at hysterectomy for other causes (n = 48).
  • The HeLa cell (cervical adenocarcinoma-derived cell) line that expresses CXCR4 was used to study the interaction between the CXCR4 receptor and stromal cell-derived factor 1alpha (SDF-1alpha).
  • We conclude CXCR4 expression is associated with cervical adenocarcinoma cell migration and proliferation, and primary cervical adenocarcinoma cells expressing CXCR4 are significantly more likely to metastasize to pelvic lymph nodes.
  • [MeSH-major] Adenocarcinoma / pathology. Lymphatic Metastasis. Receptors, CXCR4 / metabolism. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adult. Cell Line, Tumor. Cell Movement / drug effects. Cell Proliferation / drug effects. Cell Survival / drug effects. Chemokine CXCL12. Chemokines, CXC / metabolism. Chemokines, CXC / pharmacology. Female. HeLa Cells. Humans. Lymph Nodes / metabolism. Middle Aged. Mitogen-Activated Protein Kinase 1 / metabolism. Mitogen-Activated Protein Kinase 3 / metabolism. Oncogene Protein v-akt / metabolism. Pelvis. U937 Cells

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17504381.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CXCL12 protein, human; 0 / Chemokine CXCL12; 0 / Chemokines, CXC; 0 / Receptors, CXCR4; EC 2.7.11.1 / Oncogene Protein v-akt; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 1; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 3
  •  go-up   go-down


21. Takehara M, Nishioka Y, Saito T, Baba T, Suzuki T, Ito E, Kudo R: A case of stage-IVb cervical adenocarcinoma successfully treated by combination chemotherapy: case report. J Obstet Gynaecol Res; 2000 Apr;26(2):133-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of stage-IVb cervical adenocarcinoma successfully treated by combination chemotherapy: case report.
  • A 54-year-old patient with a Stage IVb adenocarcinoma of the cervix was treated with combination chemotherapy.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Uterine Cervical Neoplasms / drug therapy
  • [MeSH-minor] Cisplatin / administration & dosage. Doxorubicin / administration & dosage. Drug Administration Schedule. Female. Humans. Middle Aged. Mitomycin / administration & dosage. Neoplasm Staging


22. Cambruzzi E, Zettler CG, Alexandre CO: Expression of Ki-67 and squamous intraepithelial lesions are related with HPV in endocervical adenocarcinoma. Pathol Oncol Res; 2005;11(2):114-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of Ki-67 and squamous intraepithelial lesions are related with HPV in endocervical adenocarcinoma.
  • To estimate the association between human papillomavirus (HPV) status and the expression of p53, Ki-67 and bcl-2 in cases of endocervical adenocarcinoma, and the relation with squamous intraepithelial lesions (SIL) and age, 229 cases were selected, treated between 1995 and 2003 in the Hospital Nossa Senhora da Conceiçao.
  • The joint occurrence of endocervical adenocarcinoma and SIL were estimated too.
  • The presence of HPV, especially type 18 in endocervical adenocarcinoma suggests that this agent can be an important cofactor in the development and progression of glandular neoplasms of the uterine cervix.
  • The joint occurrence of endocervical adenocarcinoma and SIL may support this hypothesis.
  • HPV may promote an increased proliferation index in endocervical adenocarcinoma, shown by the expression of Ki-67.
  • [MeSH-major] Adenocarcinoma / virology. Ki-67 Antigen / metabolism. Papillomaviridae / pathogenicity. Papillomavirus Infections / pathology. Uterine Cervical Neoplasms / virology
  • [MeSH-minor] Adult. Age Distribution. Aged. Aged, 80 and over. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / virology. Cell Proliferation. Cervical Intraepithelial Neoplasia / metabolism. Cervical Intraepithelial Neoplasia / pathology. Cervical Intraepithelial Neoplasia / virology. Cervix Uteri / metabolism. Cervix Uteri / pathology. Cervix Uteri / virology. DNA, Viral / analysis. Female. Humans. Middle Aged. Proto-Oncogene Proteins c-bcl-2 / metabolism. Tumor Suppressor Protein p53 / metabolism

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Obstet Gynecol Scand. 2003 Oct;82(10):960-5 [12956848.001]
  • [Cites] Gynecol Oncol. 1990 Feb;36(2):246-9 [2298414.001]
  • [Cites] Diagn Cytopathol. 1995 Dec;13(5):379-85 [8834311.001]
  • [Cites] Am J Clin Pathol. 1989 Nov;92(5):577-82 [2554717.001]
  • [Cites] Int J Cancer. 1998 Feb 9;75(4):536-45 [9466653.001]
  • [Cites] Gynecol Oncol. 2003 Sep;90(3):547-51 [13678722.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1999 Dec;8(12):1079-85 [10613340.001]
  • [Cites] Int J Gynecol Pathol. 2002 Apr;21(2):125-33 [11917221.001]
  • [Cites] Gynecol Oncol. 2002 Jul;86(1):14-8 [12079293.001]
  • [Cites] Int J Gynecol Pathol. 1995 Jul;14(3):209-16 [8600071.001]
  • [Cites] Anticancer Res. 2002 May-Jun;22(3):1655-60 [12168850.001]
  • [Cites] Gynecol Oncol. 2000 Apr;77(1):129-36 [10739702.001]
  • [Cites] Hum Pathol. 1997 Mar;28(3):309-15 [9042795.001]
  • [Cites] Int J Gynecol Pathol. 2004 Jan;23(1):1-6 [14668542.001]
  • [Cites] J Clin Oncol. 1996 Jul;14(7):2120-30 [8683245.001]
  • [Cites] Am J Epidemiol. 2004 May 1;159(9):834-42 [15105176.001]
  • [Cites] Cancer. 2002 Feb 25;96(1):5-13 [11836697.001]
  • [Cites] Mod Pathol. 2000 Mar;13(3):243-51 [10757335.001]
  • [Cites] Histopathology. 2002 Sep;41(3):185-207 [12207781.001]
  • [Cites] Histopathology. 2002 Oct;41(4):313-21 [12383213.001]
  • [Cites] Eur J Gynaecol Oncol. 2001;22(6):420-2 [11874072.001]
  • [Cites] Gynecol Oncol. 2003 Jul;90(1):15-22 [12821336.001]
  • [Cites] Mod Pathol. 1997 Mar;10(3):176-80 [9071723.001]
  • [Cites] Am J Surg Pathol. 2001 Jul;25(7):884-91 [11420459.001]
  • [Cites] Int J Gynaecol Obstet. 1998 Dec;63(3):265-70 [9989896.001]
  • [Cites] Am J Obstet Gynecol. 1998 Jan;178(1 Pt 1):113-7 [9465813.001]
  • [Cites] J Clin Pathol. 2004 Jan;57(1):68-72 [14693839.001]
  • [Cites] J Clin Pathol. 1996 Dec;49(12):957 [9038727.001]
  • [Cites] Cancer. 1995 Dec 1;76(11):2297-303 [8635035.001]
  • [Cites] Am J Pathol. 1995 Sep;147(3):545-60 [7677168.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 Mar;10(3):171-7 [11303584.001]
  • [Cites] Gynecol Oncol. 2003 Oct;91(1):51-8 [14529662.001]
  • [Cites] Cancer. 2000 Sep 15;89(6):1291-9 [11002225.001]
  • [Cites] Am J Clin Oncol. 2001 Apr;24(2):160-6 [11319292.001]
  • [Cites] Gynecol Oncol. 1999 Jul;74(1):53-60 [10385551.001]
  • [Cites] Gynecol Oncol. 2001 Aug;82(2):238-46 [11531273.001]
  • [Cites] Eur J Cancer. 2001 Jan;37(2):246-50 [11166153.001]
  • [Cites] Ann Oncol. 2000 Jun;11(6):647-63 [10942052.001]
  • [Cites] Acta Obstet Gynecol Scand. 2003 Aug;82(8):762-6 [12848649.001]
  • [Cites] APMIS. 2000 Mar;108(3):209-15 [10752690.001]
  • [Cites] Gynecol Oncol. 1989 Apr;33(1):49-53 [2703167.001]
  • [Cites] Int J Gynecol Pathol. 1999 Jul;18(3):215-9 [12090589.001]
  • [Cites] Hum Pathol. 2000 Nov;31(11):1339-40 [11112206.001]
  • [Cites] Pathol Oncol Res. 1999;5(2):95-103 [10393359.001]
  • [Cites] Int J Gynecol Pathol. 1993 Jan;12(1):64-9 [8380284.001]
  • [Cites] Ann Med. 2003;35(7):458-65 [14649328.001]
  • [Cites] Diagn Cytopathol. 1998 Jun;18(6):393-7 [9626509.001]
  • [Cites] Int J Gynecol Pathol. 1997 Jan;16(1):22-7 [8986528.001]
  • [Cites] Hum Pathol. 2002 Sep;33(9):899-904 [12378514.001]
  • (PMID = 15999157.001).
  • [ISSN] 1219-4956
  • [Journal-full-title] Pathology oncology research : POR
  • [ISO-abbreviation] Pathol. Oncol. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / DNA, Viral; 0 / Ki-67 Antigen; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


23. Bharwani N, Newland A, Tunariu N, Babar S, Sahdev A, Rockall AG, Reznek RH: MRI appearances of uterine malignant mixed müllerian tumors. AJR Am J Roentgenol; 2010 Nov;195(5):1268-75
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MRI appearances of uterine malignant mixed müllerian tumors.
  • OBJECTIVE: Uterine malignant mixed müllerian tumors (MMMTs) are rare aggressive tumors with a high incidence of lymphatic, peritoneal, and pulmonary metastases.
  • Preoperative differentiation from endometrial adenocarcinoma would be beneficial because their prognoses differ.
  • Data were compared with MRI appearances of 73 endometrial adenocarcinomas.
  • In 12% of cases, large heterogeneous MMMTs obliterated uterine architecture and were aggressive in appearance, whereas in 88% of cases, the appearances were indistinguishable from those of endometrial adenocarcinoma.
  • Significantly more MMMTs than endometrial adenocarcinomas had cervical invasion (p = 0.008) and nodal enlargement (p = 0.00008).
  • Dynamic contrast-enhanced images (available for 19 of 51 patients) obtained at less than 1 minute after administration of contrast agent showed MMMT enhancement to be hypointense (42%; 5/12 patients) or isointense (33%; 4/12 patients) to myometrium; between 1 and 4 minutes after administration of contrast agent, tumors were hypointense (58%; 7/12 patients); and at more than 4 minutes after administration of contrast agent (n = 18), MMMTs were isointense in 56% of cases.
  • This finding is significantly different from that for endometrial adenocarcinoma, where enhancement is less than that of myometrium in 90% of cases (p = 4 × 10⁻⁸).
  • [MeSH-major] Magnetic Resonance Imaging / methods. Mixed Tumor, Mullerian / pathology. Uterine Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Aged. Aged, 80 and over. Chi-Square Distribution. Contrast Media. Endometrial Neoplasms / pathology. Female. Humans. Meglumine. Middle Aged. Organometallic Compounds. Retrospective Studies

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20966339.001).
  • [ISSN] 1546-3141
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Organometallic Compounds; 0 / gadoterate meglumine; 6HG8UB2MUY / Meglumine
  •  go-up   go-down


24. Epaulard O, Moro D, Langin T, Devouassoux G, Brambilla C: Bronchorrhea revealing cervix adenocarcinoma metastastic to the lung. Lung Cancer; 2001 Feb-Mar;31(2-3):331-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bronchorrhea revealing cervix adenocarcinoma metastastic to the lung.
  • We report the case of a woman presenting lung metastases of a cervical adenocarcinoma revealed by bronchorrhea, eventually identified as ectopic cervical mucus.
  • Treatment included anticancer drugs and erythromycin, the latter in order to reduce the bronchorrhea, with eventually poor efficacy.
  • This observation illustrates the importance of respiratory signs in the post-therapeutic follow up of cancer, especially cough and bronchorrhea in adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / secondary. Adenocarcinoma, Bronchiolo-Alveolar / secondary. Lung Neoplasms / secondary. Mucus / secretion. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Cough / etiology. Diagnosis, Differential. Female. Humans


25. Gurzov EN, Izquierdo M: RNA interference against Hec1 inhibits tumor growth in vivo. Gene Ther; 2006 Jan;13(1):1-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Hec1 (highly expressed in cancer) plays an important role in chromosome segregation by interacting with a subset of checkpoint proteins that survey proper chromosome alignment and bipolar spindle attachment.
  • Vector-expressed short hairpin RNAs (shRNAs) caused very efficient depletion of the target protein, cellular arrest and considerable mitotic catastrophe induction 96 h post infection in human cervix-adenocarcinoma (HeLa) and glioblastoma (U-373-MG) cell lines.
  • Furthermore, adenocarcinomas induced in the flanks of nude mice show significant reduction in size compared with control when treated with either Hec1-shRNA retroviruses or adenoviruses.
  • These results indicate that depletion of Hec1 could be used as a new strategy to block the dividing cell, and therefore against cancer.
  • [MeSH-major] Genetic Therapy / methods. Neoplasms / therapy. Nuclear Proteins / genetics. RNA Interference. RNA, Small Interfering / genetics
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / therapy. Adenoviridae / genetics. Animals. Brain Neoplasms / pathology. Brain Neoplasms / therapy. Chromosome Segregation / drug effects. Female. Flow Cytometry. Genetic Vectors / genetics. Genetic Vectors / therapeutic use. Glioblastoma / pathology. Glioblastoma / therapy. HeLa Cells. Humans. Mice. Mice, Nude. Microscopy, Fluorescence. Mitosis / drug effects. Neoplasm Transplantation. Retroviridae / genetics. Uterine Cervical Neoplasms / pathology. Uterine Cervical Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16121206.001).
  • [ISSN] 0969-7128
  • [Journal-full-title] Gene therapy
  • [ISO-abbreviation] Gene Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / NDC80 protein, human; 0 / Nuclear Proteins; 0 / RNA, Small Interfering
  •  go-up   go-down


26. Sleeman MA, Fraser JK, Murison JG, Kelly SL, Prestidge RL, Palmer DJ, Watson JD, Kumble KD: B cell- and monocyte-activating chemokine (BMAC), a novel non-ELR alpha-chemokine. Int Immunol; 2000 May;12(5):677-89
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumour panel blots showed that BRAK was down-regulated in cervical adenocarcinoma and uterine leiomyoma, but was up-regulated in breast invasive ductal carcinoma.
  • The s.c. injection of KS1 creates a mixed inflammatory response in Nude and C3H/HeJ mice.
  • We propose the name B cell- and monocyte-activating chemokine (BMAC) for this molecule to reflect the described biological functions.
  • [MeSH-minor] Amino Acid Sequence. Animals. Base Sequence. Blotting, Northern. Cell Line. Chemotaxis / drug effects. Flow Cytometry. Gene Library. Humans. Keratinocytes / immunology. Mice. Mice, Inbred C3H. Mice, Nude. Molecular Sequence Data. Odontogenic Cysts / immunology. RNA, Messenger / analysis. Skin / drug effects. Skin / immunology

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10784614.001).
  • [ISSN] 0953-8178
  • [Journal-full-title] International immunology
  • [ISO-abbreviation] Int. Immunol.
  • [Language] eng
  • [Databank-accession-numbers] GENBANK/ AF044196/ AF073957/ AF144754
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] ENGLAND
  • [Chemical-registry-number] 0 / CXCL14 protein, mouse; 0 / Chemokines, CXC; 0 / RNA, Messenger
  •  go-up   go-down


27. Abhishek A, Ouseph MM, Sharma P, Kamal V, Sharma M: Bulky scalp metastasis and superior sagittal sinus thrombosis from a cervical adenocarcinoma: an unusual case. J Med Imaging Radiat Oncol; 2008 Feb;52(1):91-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bulky scalp metastasis and superior sagittal sinus thrombosis from a cervical adenocarcinoma: an unusual case.
  • Distant cutaneous metastases from cervical malignancies are uncommon, with scalp metastases being exceptional events.
  • We present the case of a 53-year-old postmenopausal lady with adenocarcinoma of the uterine cervix that metastasized to the scalp with superior sagittal sinus thrombosis 8 months after diagnosis.
  • In contrast to the seven prior cases of scalp metastases of cervical squamous cell carcinoma reported in published reports, ours is the first documentation of such an occurrence in cervical adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Head and Neck Neoplasms / secondary. Scalp / pathology. Sinus Thrombosis, Intracranial / etiology. Skin Neoplasms / secondary. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Cervix Uteri / radiography. Cervix Uteri / surgery. Epilepsy, Tonic-Clonic / drug therapy. Epilepsy, Tonic-Clonic / etiology. Female. Humans. Hysterectomy. Magnetic Resonance Imaging / methods. Middle Aged. Tomography, X-Ray Computed / methods


28. Ueda JY, Tezuka Y, Banskota AH, Tran QL, Tran QK, Saiki I, Kadota S: Antiproliferative activity of cardenolides isolated from Streptocaulon juventas. Biol Pharm Bull; 2003 Oct;26(10):1431-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • ) MERR. were examined for their antiproliferative activity toward three human-derived (HT-1080 fibrosarcoma, lung A549 adenocarcinoma, cervix HeLa adenocarcinoma) and three murine-derived (colon 26-L5 carcinoma, Lewis lung carcinoma, B16-BL6 melanoma) cell lines.
  • [MeSH-minor] Animals. Cell Line, Tumor. DNA Fragmentation / drug effects. DNA Fragmentation / physiology. Humans. Mice. Plant Extracts / chemistry. Plant Extracts / isolation & purification. Plant Extracts / pharmacology. Plant Roots

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14519950.001).
  • [ISSN] 0918-6158
  • [Journal-full-title] Biological & pharmaceutical bulletin
  • [ISO-abbreviation] Biol. Pharm. Bull.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Cardenolides; 0 / Growth Inhibitors; 0 / Plant Extracts
  •  go-up   go-down


29. Gray A, Raff AB, Chiriva-Internati M, Chen SY, Kast WM: A paradigm shift in therapeutic vaccination of cancer patients: the need to apply therapeutic vaccination strategies in the preventive setting. Immunol Rev; 2008 Apr;222:316-27
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A paradigm shift in therapeutic vaccination of cancer patients: the need to apply therapeutic vaccination strategies in the preventive setting.
  • An extraordinary variety of potential therapeutic vaccine strategies directed against a wide variety of tumor antigens has been explored in clinical trials.
  • To date, none of these cancer immunotherapies have been approved by the Food and Drug Administration for use in humans.
  • A significant problem is that the vast majority of such clinical trials are carried out in patients with advanced or metastatic cancer.
  • Even in cases where patients are immunized in the adjuvant setting, where there is minimal residual disease, vaccines directed against tumor-associated antigens have failed to mediate eradication of tumors in the overwhelming majority of cases.
  • Recently, we and others have experimented with administering therapeutic cancer vaccines in the preventive setting.
  • These studies have demonstrated that early vaccination is extremely effective in eliciting an anti-tumor immune response that leads to unprecedented improvements in the survival of mice that spontaneously develop cancer.
  • Certain human cancers, notably prostate adenocarcinoma and cervical cancer, can currently be detected at very early stages of carcinogenesis.
  • Therapeutic vaccines are available for these diseases, opening up the possibility of administering vaccinations early to patients diagnosed with pre-malignant lesions to halt disease progression.
  • In addition, new technologies have become available in the past decade that will soon yield very sensitive and specific diagnostic tests for a plethora of other cancers.
  • Earlier detection of these cancers, combined with existing vaccines directed against them, will soon make them targets for therapeutic vaccination in the preventive setting.
  • The ability to immunize patients at the very earliest stages of carcinogenesis, when they have fully competent immune systems, has the potential to cause a paradigm shift in how therapeutic cancer vaccines are tested and used clinically.
  • [MeSH-major] Cancer Vaccines / therapeutic use. Immunotherapy / methods. Neoplasms / immunology
  • [MeSH-minor] Animals. Antigens, Neoplasm / immunology. Female. Gene Expression Regulation, Neoplastic. Humans. Immune Tolerance / immunology. Immunocompromised Host. Immunotherapy, Adoptive. Male. Mice. Papillomaviridae / immunology. Papillomavirus Infections / immunology. Papillomavirus Infections / therapy. Papillomavirus Vaccines / immunology. Viral Vaccines / immunology

  • COS Scholar Universe. author profiles.
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18364011.001).
  • [ISSN] 1600-065X
  • [Journal-full-title] Immunological reviews
  • [ISO-abbreviation] Immunol. Rev.
  • [Language] eng
  • [Grant] United States / NIGMS NIH HHS / GM / T32 GM 067587
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Cancer Vaccines; 0 / Papillomavirus Vaccines; 0 / Viral Vaccines
  • [Number-of-references] 90
  •  go-up   go-down


30. Jha AK, Nikbakht M, Parashar G, Shrivastava A, Capalash N, Kaur J: Reversal of hypermethylation and reactivation of the RARβ2 gene by natural compounds in cervical cancer cell lines. Folia Biol (Praha); 2010;56(5):195-200
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reversal of hypermethylation and reactivation of the RARβ2 gene by natural compounds in cervical cancer cell lines.
  • Reactivation of tumour suppressor genes that have been silenced by promoter methylation is a very attractive molecular target for cancer therapy.
  • The treatment of a squamous cervical cancer cell line, SiHa, with 20 μM curcumin and genistein resulted in demethylation of promoter of the RARβ2 gene and led to the reactivation of the gene.
  • In HeLa cells (an adenocarcinoma cervical cancer cell line) there was also reversal of hypermethylation of the RARβ2 gene after six days of treatment with 20 μM curcumin.
  • This is the first report to show the reversal of hypermethylation of the RARβ2 gene by genistein and curcumin in cervical cancer cell lines.
  • Furthermore, these compounds acted as doublepronged agents as they caused apoptosis in the treated cervical cancer cell lines in addition to reversal of promoter hypermethylation.
  • [MeSH-major] Antineoplastic Agents. Curcumin. DNA Methylation / drug effects. Genistein. Receptors, Retinoic Acid / genetics. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / genetics. Uterine Cervical Neoplasms / physiopathology
  • [MeSH-minor] Allyl Compounds / pharmacology. Biological Products / pharmacology. Cell Line, Tumor. Female. Humans. Sulfides / pharmacology

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • Hazardous Substances Data Bank. GENISTEIN .
  • Hazardous Substances Data Bank. CURCUMIN .
  • Hazardous Substances Data Bank. ALLYL SULFIDE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21138650.001).
  • [ISSN] 0015-5500
  • [Journal-full-title] Folia biologica
  • [ISO-abbreviation] Folia Biol. (Praha)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Czech Republic
  • [Chemical-registry-number] 0 / Allyl Compounds; 0 / Antineoplastic Agents; 0 / Biological Products; 0 / Receptors, Retinoic Acid; 0 / Sulfides; 0 / retinoic acid receptor, beta2, human; 60G7CF7CWZ / allyl sulfide; DH2M523P0H / Genistein; IT942ZTH98 / Curcumin
  •  go-up   go-down


31. Ahn WS, Bae SM, Huh SW, Lee JM, Namkoong SE, Han SJ, Kim CK, Kim JK, Kim YW: Necrosis-like death with plasma membrane damage against cervical cancer cells by photodynamic therapy. Int J Gynecol Cancer; 2004 May-Jun;14(3):475-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Necrosis-like death with plasma membrane damage against cervical cancer cells by photodynamic therapy.
  • In order to elucidate the antitumor effect of photodynamic therapy (PDT) using the photosensitizing agent hematoporphyrin derivative (Photogem) and a diode laser, we evaluated the cell death of uterine cancer cell lines (CaSki, HT3, HeLa, and SKOV-3) and mice transplanted with TC-1 lung cancer cells.
  • Also, PDT-induced damage of cancer cells was almost entirely confined to necrosis of the tumor cells in the early time courses.
  • [MeSH-major] Cervix Uteri / cytology. Photochemotherapy. Photosensitizing Agents / pharmacology. Uterine Cervical Neoplasms / drug therapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Animals. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / pathology. Cell Line, Tumor / drug effects. Cell Line, Tumor / radiation effects. Female. Flow Cytometry. Humans. Mice. Mice, Inbred C57BL. Necrosis


32. Tian Y, Wu P, Luo AY, Xi L, Zhou JF, Ma D: [Expression and significance of Smad2/3 and HPV16 E7 in cervical intraepithelial neoplasia and cervical carcinoma]. Ai Zheng; 2007 Sep;26(9):967-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression and significance of Smad2/3 and HPV16 E7 in cervical intraepithelial neoplasia and cervical carcinoma].
  • BACKGROUND & OBJECTIVE: Smad proteins are downstream signal proteins of the transforming growth factor-beta (TGF-beta) superfamily, which are intimately related to the genesis of many human carcinomas.
  • Human papillomavirus (HPV) is an important carcinogenic agent of cervical cancer.
  • However, their relationship in the genesis of cervical cancer is unclear.
  • This study was to detect the expression of Smad2/3 and HPV16 E7 protein in different cervical lesions, and to explore their possible roles in tumor genesis and progression.
  • METHODS: The expression of Smad2/3 and HPV16 E7 in 20 specimens of chronic cervicitis, 30 specimens of cervical intraepithelial neoplasia (CIN), and 30 specimens of cervical cancer was detected by SP immunohistochemistry.
  • RESULTS: The positive rates of Smad2/3 were significantly lower in cervicitis and CIN than in cervical cancer (50.0% and 73.3% vs. 93.3%, P<0.05), and significantly lower in cervicitis than in CINIII(P<0.05).
  • The positive rates of HPV16 E7 were 60.0% in cervicitis, 66.7% in CIN, and 83.3% in cervical cancer (P>0.05).
  • The expression of Smad2/3 in cervical cancer had no correlation to clinical stage, pathologic classification, histological grade, and lymph node involvement(P>0.05).
  • CONCLUSIONS: Overexpression of Smad2/3 may be involved in the genesis of cervical cancer.
  • It is closely correlated to HPV infection in cervical carcinoma.
  • [MeSH-major] Carcinoma, Squamous Cell / metabolism. Cervical Intraepithelial Neoplasia / metabolism. Oncogene Proteins, Viral / metabolism. Smad2 Protein / metabolism. Uterine Cervical Neoplasms / metabolism
  • [MeSH-minor] Adenocarcinoma / metabolism. Adult. Biomarkers, Tumor / metabolism. Cervix Uteri / metabolism. Female. Humans. Immunohistochemistry. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Papillomavirus E7 Proteins. Smad3 Protein / metabolism. Up-Regulation. Uterine Cervicitis / metabolism

  • Genetic Alliance. consumer health - Cervical Intraepithelial Neoplasia.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17927854.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Oncogene Proteins, Viral; 0 / Papillomavirus E7 Proteins; 0 / SMAD2 protein, human; 0 / SMAD3 protein, human; 0 / Smad2 Protein; 0 / Smad3 Protein; 0 / oncogene protein E7, Human papillomavirus type 16
  •  go-up   go-down


33. Kim SS, Won SJ, Kim NJ, Yoo JK, Bae K, Lee KT: 3-Oxoolean-12-en-27-oic acid isolated from Aceriphyllum rossii induces caspase-8-dependent apoptosis in human promyelocytic leukemia HL-60 cells. Biol Pharm Bull; 2009 Jan;32(1):91-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • 3-OA-treated HL-60 cells and HeLa human cervix adenocarcinoma cells displayed several apoptotic features, such as, DNA fragmentation, DNA laddering by agarose gel electrophoresis, and hypodiploid DNA contents by flow cytometry, and 3-OA also caused the activations of caspase-8, -9 and -3.
  • [MeSH-major] Apoptosis / drug effects. Caspase 8 / metabolism. HL-60 Cells / drug effects. Saxifragaceae / chemistry. Triterpenes / pharmacology
  • [MeSH-minor] Amino Acid Chloromethyl Ketones / pharmacology. Cell Line, Transformed. Dose-Response Relationship, Drug. Fas Ligand Protein / genetics. Fas Ligand Protein / metabolism. Fas-Associated Death Domain Protein / genetics. Fas-Associated Death Domain Protein / metabolism. Humans. Neuroprotective Agents / pharmacology. RNA, Messenger / metabolism. Serine Endopeptidases / genetics. Serine Endopeptidases / metabolism. Tetrazolium Salts. Thiazoles. Time Factors

  • Hazardous Substances Data Bank. METHYLTHIAZOLETETRAZOLIUM .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19122287.001).
  • [ISSN] 0918-6158
  • [Journal-full-title] Biological & pharmaceutical bulletin
  • [ISO-abbreviation] Biol. Pharm. Bull.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Amino Acid Chloromethyl Ketones; 0 / FADD protein, human; 0 / FASLG protein, human; 0 / Fas Ligand Protein; 0 / Fas-Associated Death Domain Protein; 0 / Neuroprotective Agents; 0 / RNA, Messenger; 0 / Tetrazolium Salts; 0 / Thiazoles; 0 / Triterpenes; 0 / benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone; 298-93-1 / thiazolyl blue; EC 3.4.21.- / HABP2 protein, human; EC 3.4.21.- / Serine Endopeptidases; EC 3.4.22.- / Caspase 8
  •  go-up   go-down


34. Manchana T, Triratanachat S, Sirisabya N, Vasuratna A, Termrungruanglert W, Tresukosol D: Prevalence and prognostic significance of COX-2 expression in stage IB cervical cancer. Gynecol Oncol; 2006 Mar;100(3):556-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevalence and prognostic significance of COX-2 expression in stage IB cervical cancer.
  • OBJECTIVES: To evaluate the prevalence of cyclooxygenase-2 (COX-2), correlation with various clinicopathologic factors and prognostic significance of COX-2 in stage IB cervical cancer patients.
  • METHODS: 89 paraffin-embedded specimens of patients with stage IB cervical cancer underwent radical hysterectomy and pelvic lymphadenectomy at King Chulalongkorn Memorial Hospital during 1 January 1997-31 December 2002 and were stained with polyclonal goat antiserum against COX-2 using immunohistochemical method.
  • RESULTS: The prevalence of positive COX-2 expression in stage IB cervical cancer in this study was 49.4%.
  • Positive COX-2 expression in cervical adenocarcinoma was higher than squamous cell carcinoma (86.7% versus 40.6%, P < 0.05) and significantly expressed when lymph node metastasis was presented (100% versus 46.4%, P < 0.05).
  • CONCLUSIONS: Strong correlation was found in cervical adenocarcinoma and lymph node metastasis.
  • However, COX-2 expression failed to demonstrate as a significant prognostic factor in stage IB cervical cancer.
  • [MeSH-major] Cyclooxygenase 2 / biosynthesis. Uterine Cervical Neoplasms / enzymology
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / enzymology. Adenocarcinoma / pathology. Adenocarcinoma / surgery. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / enzymology. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / surgery. Disease-Free Survival. Female. Humans. Immunohistochemistry. Middle Aged. Neoadjuvant Therapy. Neoplasm Staging


35. Araki S, Miyagi Y, Kawanishi K, Yamamoto J, Hongo A, Kodama J, Yoshinouchi M, Kudo T: Neoadjuvant treatment with docetaxel and the effects of irradiation for human ovarian adenocarcinoma and cervical squamous cell carcinoma in vitro. Acta Med Okayama; 2002 Feb;56(1):13-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoadjuvant treatment with docetaxel and the effects of irradiation for human ovarian adenocarcinoma and cervical squamous cell carcinoma in vitro.
  • In this study, the authors attempted to evaluate the radiosensitizing effects in terms of cell survival and DNA single-strand breaks in a human ovarian adenocarcinoma cell line (known as line BG-1) and a human cervical squamous cell carcinoma cell line (known as line SiHa).
  • [MeSH-major] Adenocarcinoma. Antineoplastic Agents, Phytogenic / pharmacology. Carcinoma, Squamous Cell. Ovarian Neoplasms. Paclitaxel / analogs & derivatives. Paclitaxel / pharmacology. Taxoids. Uterine Cervical Neoplasms
  • [MeSH-minor] Combined Modality Therapy. DNA, Single-Stranded / radiation effects. Female. Humans. In Vitro Techniques. Neoplastic Stem Cells / drug effects. Neoplastic Stem Cells / radiation effects. Radiation-Sensitizing Agents / pharmacology. Tumor Cells, Cultured / drug effects. Tumor Cells, Cultured / radiation effects

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11873939.001).
  • [ISSN] 0386-300X
  • [Journal-full-title] Acta medica Okayama
  • [ISO-abbreviation] Acta Med. Okayama
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / DNA, Single-Stranded; 0 / Radiation-Sensitizing Agents; 0 / Taxoids; 15H5577CQD / docetaxel; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


36. de Inés C, Argandoña VH, Rovirosa J, San-Martín A, Díaz-Marrero AR, Cueto M, González-Coloma A: Cytotoxic activity of halogenated monoterpenes from Plocamium cartilagineum. Z Naturforsch C; 2004 May-Jun;59(5-6):339-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Nine halogenated monoterpenes isolated from the red alga Plocamium cartilagineum have been evaluated for their cytotoxic effects on the tumor cell lines CT26 (murine colon adenocarcinoma), SW480 (human colon adenocarcinoma), HeLa (human cervical adenocarcinoma) and SkMel28 (human malignant melanoma) with several multidrug resistance mechanisms and the mammalian non-tumor cell line CHO (Chinese hamster ovary cells).
  • Compounds 1, 2, 3, and 5 exhibited selective cytotoxicity against colon and cervical adenocarcinoma cells.
  • Interestingly, the effect of compound 3 was specific and irreversible to human colon adenocarcinoma SW480 cells, which overexpress the transmembrane P-glycoprotein often related to chemoresistance.
  • [MeSH-major] Cell Survival / drug effects. HeLa Cells / drug effects. Monoterpenes / pharmacology. Plocamium / chemistry
  • [MeSH-minor] Adenocarcinoma. Animals. Antineoplastic Agents / toxicity. CHO Cells. Cell Line, Tumor / drug effects. Colonic Neoplasms. Cricetinae. Cricetulus. Drug Resistance, Multiple. Humans. Melanoma. Mice

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18998398.001).
  • [ISSN] 0939-5075
  • [Journal-full-title] Zeitschrift für Naturforschung. C, Journal of biosciences
  • [ISO-abbreviation] Z. Naturforsch., C, J. Biosci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Monoterpenes
  •  go-up   go-down


37. Mena-Rejon G, Caamal-Fuentes E, Cantillo-Ciau Z, Cedillo-Rivera R, Flores-Guido J, Moo-Puc R: In vitro cytotoxic activity of nine plants used in Mayan traditional medicine. J Ethnopharmacol; 2009 Jan 30;121(3):462-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vitro cytotoxic activity of nine plants used in Mayan traditional medicine.
  • ETHNOPHARMACOLOGICAL RELEVANCE: Plants have been used in folk medicine by Mayan ancient people from the Yucatan Peninsula, Mexico, to treat some diseases considered as cancer diseases such as chronic wounds or tumors.
  • AIM OF THE STUDY: We collected a selection of nine plants in order to investigate their cytotoxic activity against cancer cell lines.
  • MATERIALS AND METHODS: Methanolic extracts were tested for their cytotoxicity using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay on four cancer cell lines; nasopharynx carcinoma (KB), laryngeal carcinoma (Hep-2), cervix adenocarcinoma (HeLa), and cervix squamous carcinoma cells (SiHa) and one normal cell line; canine kidney (MDCK).
  • CONCLUSIONS: Hamelia patens, Dioon spinulosum and Gossypium schottii demonstrated promising cytotoxic activity and have been selected for future bio-guided fractionation and isolation of active cytotoxic compounds.
  • [MeSH-major] Angiosperms. Cytotoxins / therapeutic use. Neoplasms / drug therapy. Phytotherapy. Plant Extracts / therapeutic use
  • [MeSH-minor] Animals. Cell Line, Tumor. Dogs. Female. Humans. Indians, North American. Medicine, Traditional. Mexico. Plants, Medicinal

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19071205.001).
  • [ISSN] 1872-7573
  • [Journal-full-title] Journal of ethnopharmacology
  • [ISO-abbreviation] J Ethnopharmacol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Cytotoxins; 0 / Plant Extracts
  •  go-up   go-down


38. Choi SJ, Brylev KA, Xu JZ, Mironov YV, Fedorov VE, Sohn YS, Kim SJ, Choy JH: Cellular uptake and cytotoxicity of octahedral rhenium cluster complexes. J Inorg Biochem; 2008 Nov;102(11):1991-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cellular uptake behavior of a novel class of octahedral rhenium cluster compounds, hexahydroxo complexes K(4)[{Re(6)S(8)}(OH)(6)].8H(2)O (1) and K(4)[{Re(6)Se(8)}(OH)(6)].8H(2)O (2), was evaluated in human cervical adenocarcinoma HeLa cells.
  • According to the cytotoxicity evaluation test, both rhenium clusters 2 and 3 did not exhibit acute cytotoxic effects up to 50 microM, at the practical concentration level of biological applications.
  • It is, therefore, expected that the rhenium cluster complexes can be promising potential candidates as diagnostic agents for medical treatment.
  • [MeSH-minor] Biological Transport. Cell Survival. Chelating Agents / chemistry. Chelating Agents / metabolism. Chelating Agents / toxicity. Female. HeLa Cells. Humans. Microscopy, Confocal

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18783832.001).
  • [ISSN] 1873-3344
  • [Journal-full-title] Journal of inorganic biochemistry
  • [ISO-abbreviation] J. Inorg. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chelating Agents; 0 / Organometallic Compounds; 7440-15-5 / Rhenium
  •  go-up   go-down


39. Haie-Meder C, Lhommé C, de Crevoisier R, Morice P, Resbeut M: [Concomitant radiochemotherapy in cancer of the cervix uteri: modifications of the standards]. Cancer Radiother; 2000 Nov;4 Suppl 1:134s-140s
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Concomitant radiochemotherapy in cancer of the cervix uteri: modifications of the standards].
  • [Transliterated title] Radiochimiothérapie concomitante dans les cancers du col de l'utérus: modifications des standards.
  • For a long time, combined external irradiation and brachytherapy has been considered as the standard treatment in patients with advanced cervical cancers.
  • The differences, however, were less significant in patients with advanced stages III or IVA.
  • The results of these randomized trials have led to a modification in the standard of treatment in these poor prognosis cervix cancers.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / radiotherapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / radiotherapy. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Cisplatin / administration & dosage. Combined Modality Therapy. Female. Fluorouracil / administration & dosage. Humans. Hydroxyurea / administration & dosage. Hysterectomy. Metaplasia. Neoplasm Staging. Patient Selection. Radiotherapy Dosage. Randomized Controlled Trials as Topic. Survival Analysis

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • Hazardous Substances Data Bank. HYDROXYUREA .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11194951.001).
  • [ISSN] 1278-3218
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil; X6Q56QN5QC / Hydroxyurea
  • [Number-of-references] 17
  •  go-up   go-down


40. Brand C, Ségard P, Plouvier P, Formstecher P, Danzé PM, Lefebvre P: Selective alteration of gene expression in response to natural and synthetic retinoids. BMC Pharmacol; 2002 May 13;2:13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Retinoids are very potent inducers of cellular differentiation and apoptosis, and are efficient anti-tumoral agents.
  • Synthetic retinoids are designed to restrict their toxicity and side effects, mostly by increasing their selectivity toward each isotype of retinoic acids receptors (RARalpha,beta, gamma and RXRalpha, beta, gamma).
  • RESULTS: Using the differential display mRNA technique, we identified several genes on the basis of their differential induction by natural or synthetic retinoids in human cervix adenocarcinoma cells.
  • [MeSH-major] Gene Expression Regulation, Neoplastic / drug effects. Promoter Regions, Genetic / drug effects. Receptors, Retinoic Acid / metabolism. Retinoids / pharmacology
  • [MeSH-minor] Animals. Apoptosis. Cell Differentiation / drug effects. Female. HeLa Cells. Humans. Mice. RNA, Messenger / drug effects. RNA, Messenger / metabolism. Retinoid X Receptors. Transcription Factors / antagonists & inhibitors. Transcription Factors / metabolism. Tumor Cells, Cultured

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Skin Pharmacol. 1992;5(1):57-65 [1315557.001]
  • [Cites] Cell. 1992 Oct 2;71(1):73-85 [1327537.001]
  • [Cites] Int J Dev Biol. 1993 Mar;37(1):135-40 [8507558.001]
  • [Cites] J Biol Chem. 2000 Jan 7;275(1):642-50 [10617662.001]
  • [Cites] Curr Pharm Des. 2000 Jan;6(1):25-58 [10637371.001]
  • [Cites] Gene. 2000 Apr 4;246(1-2):9-21 [10767523.001]
  • [Cites] Blood. 2000 Aug 15;96(4):1496-504 [10942397.001]
  • [Cites] Cell. 1978 Oct;15(2):393-403 [214238.001]
  • [Cites] Bioessays. 1994 May;16(5):343-8 [8024542.001]
  • [Cites] Vitam Horm. 1994;49:327-82 [7810073.001]
  • [Cites] Nature. 1995 Mar 2;374(6517):91-4 [7870181.001]
  • [Cites] Biochemistry. 1995 Apr 25;34(16):5477-85 [7727406.001]
  • [Cites] EMBO J. 1995 Aug 1;14(15):3741-51 [7641693.001]
  • [Cites] Dev Biol. 1995 Aug;170(2):420-33 [7649373.001]
  • [Cites] Nature. 1995 Oct 5;377(6548):397-404 [7566114.001]
  • [Cites] Cold Spring Harb Symp Quant Biol. 1994;59:85-95 [7587135.001]
  • [Cites] Cell. 1996 May 3;85(3):403-14 [8616895.001]
  • [Cites] EMBO J. 1996 Jul 15;15(14):3667-75 [8670870.001]
  • [Cites] Mol Cell Biol. 1996 Aug;16(8):4137-46 [8754812.001]
  • [Cites] Biochim Biophys Acta. 1996 Jul 31;1275(3):161-203 [8695634.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Jul 23;93(15):7567-71 [8755515.001]
  • [Cites] Nature. 1996 Sep 5;383(6595):99-103 [8779723.001]
  • [Cites] J Biol Chem. 1996 Sep 13;271(37):22692-6 [8798442.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Oct 1;93(20):10626-31 [8855229.001]
  • [Cites] J Biol Chem. 1997 May 2;272(18):12062-8 [9115274.001]
  • [Cites] Biochem Biophys Res Commun. 1997 May 8;234(1):278-82 [9169003.001]
  • [Cites] Nature. 1997 Jun 12;387(6634):677-84 [9192892.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Aug 5;94(16):8479-84 [9238002.001]
  • [Cites] Science. 1997 Aug 15;277(5328):965-8 [9252329.001]
  • [Cites] Mol Cell Biol. 1997 Nov;17(11):6598-608 [9343423.001]
  • [Cites] Genes Dev. 1997 Dec 15;11(24):3351-64 [9407028.001]
  • [Cites] J Biol Chem. 1998 Mar 20;273(12):7066-71 [9507016.001]
  • [Cites] J Biol Chem. 1998 May 15;273(20):12288-95 [9575180.001]
  • [Cites] Nature. 1998 May 21;393(6682):284-9 [9607768.001]
  • [Cites] Genes Dev. 1998 Jun 15;12(12):1787-800 [9637681.001]
  • [Cites] Biochemistry. 1998 Jun 30;37(26):9240-9 [9649304.001]
  • [Cites] Mol Cell Biol. 1998 Aug;18(8):4719-31 [9671482.001]
  • [Cites] Cancer Res. 1998 Dec 1;58(23):5551-8 [9850093.001]
  • [Cites] Mol Biotechnol. 1998 Dec;10(3):261-7 [9951706.001]
  • [Cites] Mol Endocrinol. 1999 Feb;13(2):276-85 [9973257.001]
  • [Cites] Mol Cell Biol. 1999 Apr;19(4):3073-85 [10082574.001]
  • (PMID = 12019025.001).
  • [ISSN] 1471-2210
  • [Journal-full-title] BMC pharmacology
  • [ISO-abbreviation] BMC Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / Receptors, Retinoic Acid; 0 / Retinoid X Receptors; 0 / Retinoids; 0 / Transcription Factors; 0 / retinoic acid binding protein II, cellular; 0 / retinoic acid receptor alpha; 0 / retinoic acid receptor beta
  • [Other-IDs] NLM/ PMC113761
  •  go-up   go-down


41. Han YH, Moon HJ, You BR, Park WH: The anti-apoptotic effects of caspase inhibitors on propyl gallate-treated HeLa cells in relation to reactive oxygen species and glutathione levels. Arch Toxicol; 2009 Sep;83(9):825-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Propyl gallate (PG) as a synthetic antioxidant is widely used in processed food, cosmetics and medicinal preparations.
  • In the present study, we evaluated the anti-apoptotic effects of caspase inhibitors on PG-treated human cervix adenocarcinoma HeLa cells in relation to the changes of reactive oxygen species (ROS) and glutathione (GSH) levels.
  • [MeSH-major] Apoptosis / drug effects. Caspase Inhibitors. Glutathione / metabolism. Propyl Gallate / pharmacology. Reactive Oxygen Species / metabolism
  • [MeSH-minor] Amino Acid Chloromethyl Ketones / pharmacology. Annexin A5 / metabolism. Antioxidants / pharmacology. Caspase 3 / metabolism. Caspase 8 / metabolism. Caspase 9 / metabolism. Dose-Response Relationship, Drug. Enzyme Inhibitors / pharmacology. G1 Phase / drug effects. HeLa Cells. Humans. Oligopeptides / pharmacology. Time Factors

  • Hazardous Substances Data Bank. PROPYL GALLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19434396.001).
  • [ISSN] 1432-0738
  • [Journal-full-title] Archives of toxicology
  • [ISO-abbreviation] Arch. Toxicol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Amino Acid Chloromethyl Ketones; 0 / Annexin A5; 0 / Antioxidants; 0 / Caspase Inhibitors; 0 / Enzyme Inhibitors; 0 / Oligopeptides; 0 / Reactive Oxygen Species; 0 / benzoylcarbonyl-aspartyl-glutamyl-valyl-aspartyl-fluoromethyl ketone; 0 / benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone; 0 / benzyloxycarbonyl-leucyl-glutamyl-histidyl-aspartic acid fluoromethyl ketone; 0 / benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone; 8D4SNN7V92 / Propyl Gallate; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspase 8; EC 3.4.22.- / Caspase 9; GAN16C9B8O / Glutathione
  •  go-up   go-down


42. Giovagnini L, Ronconi L, Aldinucci D, Lorenzon D, Sitran S, Fregona D: Synthesis, characterization, and comparative in vitro cytotoxicity studies of platinum(II), palladium(II), and gold(III) methylsarcosinedithiocarbamate complexes. J Med Chem; 2005 Mar 10;48(5):1588-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This work reports on the synthesis, characterization, and in vitro cytotoxic activity of some new platinum(II), palladium(II), and gold(III) derivatives of methylsarcosinedithiocarbamate and its S-methyl ester, to study their behavior as potential antitumor agents.
  • The biological activity of these compounds, as determined by growth inhibition and apoptosis induction, has been investigated in both human leukemic promyelocites HL60 and human squamous cervical adenocarcinoma HeLa cell lines, and their activity has been compared to the well-known platinum-based anticancer agent cisplatin.
  • On the basis of these experimental results, [Pd(MSDT)X]n (MSDT = methylsarcosinedithiocarbamate; X = Cl, Br) complexes show a strong dose-dependent growth inhibition of both HL60 and HeLa cells, with IC(50) values slightly higher than those recorded for cisplatin; moreover, [Au(MSDT)X(2)] activity appears significantly higher or, at least, comparable to that of the reference drug.
  • [MeSH-major] Antineoplastic Agents / chemical synthesis. Gold. Organoplatinum Compounds / chemical synthesis. Palladium. Platinum. Sarcosine / analogs & derivatives. Thiocarbamates / chemical synthesis
  • [MeSH-minor] Apoptosis. Cell Proliferation / drug effects. Cisplatin / pharmacology. Drug Screening Assays, Antitumor. HL-60 Cells. HeLa Cells. Humans. Magnetic Resonance Spectroscopy. Models, Molecular. Spectroscopy, Fourier Transform Infrared

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. PALLADIUM, ELEMENTAL .
  • Hazardous Substances Data Bank. PLATINUM .
  • Hazardous Substances Data Bank. GOLD, ELEMENTAL .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15743200.001).
  • [ISSN] 0022-2623
  • [Journal-full-title] Journal of medicinal chemistry
  • [ISO-abbreviation] J. Med. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Organoplatinum Compounds; 0 / Thiocarbamates; 49DFR088MY / Platinum; 5TWQ1V240M / Palladium; 7440-57-5 / Gold; Q20Q21Q62J / Cisplatin; Z711V88R5F / Sarcosine
  •  go-up   go-down


43. Zannoni GF, Vellone VG, Carbone A: Morphological effects of radiochemotherapy on cervical carcinoma: a morphological study of 50 cases of hysterectomy specimens after neoadjuvant treatment. Int J Gynecol Pathol; 2008 Apr;27(2):274-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Morphological effects of radiochemotherapy on cervical carcinoma: a morphological study of 50 cases of hysterectomy specimens after neoadjuvant treatment.
  • The introduction of radiochemotherapy for treatment of advanced cervical cancers represents a new chapter in surgical pathology.
  • The study group included 50 women with a histological diagnosis of advanced cervical carcinoma (43 squamous, 3 adenosquamous, 2 adenocarcinoma, 1 glassy cell, and 1 undifferentiated; International Federation of Gynecology and Obstetrics stage Ib-III) receiving a platinum-based chemotherapy concomitant with external beam radiotherapy before radical surgery.
  • In most cases, morphological criteria are sufficient to make a diagnosis, but sometimes, the use of immunohistochemistry (keratins and CD68) is a mandatory method to reveal the nature of the lesion.
  • [MeSH-major] Carcinoma / pathology. Carcinoma, Adenosquamous / pathology. Carcinoma, Squamous Cell / pathology. Hysterectomy. Neoadjuvant Therapy / methods. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Antigens, CD / metabolism. Antigens, Differentiation, Myelomonocytic / metabolism. Biomarkers, Tumor / metabolism. Cervix Uteri / drug effects. Cervix Uteri / radiation effects. Cervix Uteri / surgery. Combined Modality Therapy. Female. Humans. Keratins / metabolism. Middle Aged

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Hysterectomy.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18317212.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Differentiation, Myelomonocytic; 0 / Biomarkers, Tumor; 0 / CD68 antigen, human; 68238-35-7 / Keratins
  •  go-up   go-down


44. Gao S, Chen J, Xu X, Ding Z, Yang YH, Hua Z, Zhang J: Galactosylated low molecular weight chitosan as DNA carrier for hepatocyte-targeting. Int J Pharm; 2003 Apr 14;255(1-2):57-68
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gal-LMWCs were used to transfer pSV-beta-galactosidase reporter gene into human hepatocellular carcinoma cell (HepG2), L-02, SMMC-7721, and human cervix adenocarcinoma cell line (HeLa) cell lines in vitro.
  • [MeSH-major] Chitin / analogs & derivatives. Disaccharides. Drug Carriers. Gene Transfer Techniques. Hepatocytes / metabolism

  • Hazardous Substances Data Bank. CHITIN UNSPECIFIED .
  • Hazardous Substances Data Bank. CALCIUM HYDROGEN PHOSPHATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12672602.001).
  • [ISSN] 0378-5173
  • [Journal-full-title] International journal of pharmaceutics
  • [ISO-abbreviation] Int J Pharm
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Calcium Phosphates; 0 / Disaccharides; 0 / Drug Carriers; 0 / Phosphatidylethanolamines; 0 / alpha-tricalcium phosphate; 0 / tetracalcium phosphate; 1398-61-4 / Chitin; 65R938S4DV / lactobionic acid; 701EKV9RMN / calcium phosphate, monobasic, anhydrous; 76391-83-8 / 1,2-dielaidoylphosphatidylethanolamine; 9012-76-4 / Chitosan; 97Z1WI3NDX / calcium phosphate; EC 3.2.1.23 / beta-Galactosidase; L11K75P92J / calcium phosphate, dibasic, anhydrous
  •  go-up   go-down


45. Marnitz S, Schmittel A, Bolbrinker J, Schmidt FP, Fons G, Kalache K, Schneider A, Köhler C: The therapeutic management of a twin pregnancy complicated by the presence of cervical cancer, following laparoscopic staging and chemotherapy, with an emphasis on cisplatin concentrations in the fetomaternal compartments amnion fluid, umbilical cord, and maternal serum. Fertil Steril; 2009 Nov;92(5):1748.e1-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The therapeutic management of a twin pregnancy complicated by the presence of cervical cancer, following laparoscopic staging and chemotherapy, with an emphasis on cisplatin concentrations in the fetomaternal compartments amnion fluid, umbilical cord, and maternal serum.
  • OBJECTIVE: To evaluate the feasibility, toxicity, and pharmacokinetics in the maternal and fetal compartments during chemotherapy in a pregnant patient with cervical cancer.
  • PATIENT: A 35-year-old woman was diagnosed with an adenocarcinoma FIGO stage IB1 of the cervix uteri at 14 weeks' gestation with twin pregnancy.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Cisplatin / therapeutic use. Pregnancy, Multiple. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adult. Amniotic Fluid / chemistry. Amniotic Fluid / metabolism. Antineoplastic Agents / therapeutic use. Feasibility Studies. Female. Fetal Blood / chemistry. Fetal Blood / metabolism. Humans. Laparoscopy. Maternal-Fetal Exchange / drug effects. Mothers. Neoplasm Staging / methods. Osmolar Concentration. Pregnancy. Pregnancy Complications, Neoplastic / drug therapy. Pregnancy Complications, Neoplastic / pathology. Twins


46. Faried LS, Faried A, Kanuma T, Aoki H, Sano T, Nakazato T, Tamura T, Kuwano H, Minegishi T: Expression of an activated mammalian target of rapamycin in adenocarcinoma of the cervix: A potential biomarker and molecular target therapy. Mol Carcinog; 2008 Jun;47(6):446-57
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of an activated mammalian target of rapamycin in adenocarcinoma of the cervix: A potential biomarker and molecular target therapy.
  • Alterations of the Akt/mTOR pathway have been observed in numerous types of cancer, thus this pathway represents an exciting new target for molecular therapeutics.
  • We investigated the expression of activated Akt (p-Akt) and mTOR (p-mTOR) in patients with adenocarcinoma of the cervix and the involvement of the p-Akt/p-mTOR pathway in response to combination of inhibitor agents, rapamycin and LY294002, with conventional therapy, cisplatin, in vitro.
  • Immunohistochemistry analysis of p-Akt and p-mTOR was conducted in 26 patients with adenocarcinoma of the cervix.
  • Western blot analysis was performed to determine the protein expression involved in response to chemotherapy in cervical cancer cell lines.
  • The results showed that p-Akt and p-mTOR were identified in 50% and 53.8% of adenocarcinoma of the cervix.
  • The expression of p-mTOR was a significant independent marker for prognosis.
  • Overall, the expression of p-mTOR is a significant prognostic marker of adenocarcinoma of the cervix and a potential molecular target for the treatment of cervical cancer.
  • Inhibition of the mTOR pathway contributes to cisplatin-induced apoptosis in cervical cancer cell lines.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / metabolism. Protein Kinases / metabolism. Uterine Cervical Neoplasms / metabolism
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / pharmacology. Antineoplastic Agents / therapeutic use. Blotting, Western. Cell Line, Tumor. Drug Screening Assays, Antitumor. Female. Humans. Immunohistochemistry. Middle Aged. Prognosis. Proto-Oncogene Proteins c-akt / metabolism. TOR Serine-Threonine Kinases

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 18058806.001).
  • [ISSN] 1098-2744
  • [Journal-full-title] Molecular carcinogenesis
  • [ISO-abbreviation] Mol. Carcinog.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; EC 2.7.- / Protein Kinases; EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt
  •  go-up   go-down


47. Alpan AS, Zencir S, Zupkó I, Coban G, Réthy B, Gunes HS, Topcu Z: Biological activity of bis-benzimidazole derivatives on DNA topoisomerase I and HeLa, MCF7 and A431 cells. J Enzyme Inhib Med Chem; 2009 Jun;24(3):844-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biological activity of bis-benzimidazole derivatives on DNA topoisomerase I and HeLa, MCF7 and A431 cells.
  • Benzimidazoles of both natural and synthetic sources are the key components of many bio-active compounds.
  • The compounds were screened via in vitro plasmid superciol relaxation assays using mammalian DNA topoisomerase I and cytostatic assays were carried out against HeLa (cervix adenocarcinoma), MCF7 (breast adenocarcinoma) and A431 (skin epidermoid carcinoma) cells for selected derivatives.
  • The inhibitory effects obtained with these derivatives are significant as these compounds can be potential sources of anticancer agents.
  • [MeSH-major] Antineoplastic Agents / chemical synthesis. Antineoplastic Agents / pharmacology. Benzimidazoles / chemical synthesis. Benzimidazoles / pharmacology. Topoisomerase I Inhibitors
  • [MeSH-minor] Animals. Breast Neoplasms / pathology. Carcinoma, Squamous Cell / pathology. Cell Line, Tumor. DNA Topoisomerases, Type I / metabolism. Female. HeLa Cells. Humans. Spectrum Analysis. Structure-Activity Relationship. Uterine Cervical Neoplasms / pathology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18951286.001).
  • [ISSN] 1475-6374
  • [Journal-full-title] Journal of enzyme inhibition and medicinal chemistry
  • [ISO-abbreviation] J Enzyme Inhib Med Chem
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzimidazoles; 0 / Topoisomerase I Inhibitors; 16656-27-2 / bis-benzimidazole; EC 5.99.1.2 / DNA Topoisomerases, Type I
  •  go-up   go-down


48. Rho YS, Min G: Relaxin does not influence the growth of human cervical adenocarcinoma (HeLa) cells in culture. Ann N Y Acad Sci; 2005 May;1041:470-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relaxin does not influence the growth of human cervical adenocarcinoma (HeLa) cells in culture.
  • This study was performed to determine whether relaxin influences the growth of human adenocarcinoma (HeLa) cells of the cervix, which has been shown to contain relaxin-binding sites and proliferate by relaxin.
  • We conclude that relaxin may have differential effects on the growth of two different cancer cell types, MCF-7 and HeLa cells.
  • [MeSH-major] Adenocarcinoma / pathology. Relaxin / pharmacology. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Cell Culture Techniques. Cell Proliferation / drug effects. Female. HeLa Cells. Humans

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15956748.001).
  • [ISSN] 0077-8923
  • [Journal-full-title] Annals of the New York Academy of Sciences
  • [ISO-abbreviation] Ann. N. Y. Acad. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 9002-69-1 / Relaxin
  •  go-up   go-down


49. Vandevyver CD, Chauvin AS, Comby S, Bünzli JC: Luminescent lanthanide bimetallic triple-stranded helicates as potential cellular imaging probes. Chem Commun (Camb); 2007 May 7;(17):1716-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Water-soluble triple-stranded [Ln(2)(L)(3)] helicates have been successfully tested as imaging probes in human cervical adenocarcinoma cells (HeLa), the complex being not toxic and clearly staining their cytoplasm in a concentration-dependent manner.
  • [MeSH-minor] Cell Proliferation / drug effects. HeLa Cells. Humans. Ligands. Luminescent Measurements. Molecular Structure

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17457418.001).
  • [ISSN] 1359-7345
  • [Journal-full-title] Chemical communications (Cambridge, England)
  • [ISO-abbreviation] Chem. Commun. (Camb.)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Lanthanoid Series Elements; 0 / Ligands
  •  go-up   go-down


50. Tabata T, Nishiura K, Yanoh K, Okugawa T, Obata H, Tanaka K, Toyoda N: A pilot study of neoadjuvant chemotherapy with mitomycin C, etoposide, cisplatin, and epirubicin for adenocarcinoma of the cervix. Int J Clin Oncol; 2004 Feb;9(1):59-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A pilot study of neoadjuvant chemotherapy with mitomycin C, etoposide, cisplatin, and epirubicin for adenocarcinoma of the cervix.
  • BACKGROUND: To evaluate the efficacy and toxicity of the combination of mitomycin C, etoposide, cisplatin, and epirubicin (MEPA) as neoadjuvant therapy for patients with cervical adenocarcinoma.
  • METHODS: Fourteen patients with cervical adenocarcinoma received neoadjuvant MEPA therapy followed by radical hysterectomy.
  • [MeSH-major] Adenocarcinoma / therapy. Antineoplastic Agents / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neoadjuvant Therapy. Uterine Cervical Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Antibiotics, Antineoplastic / administration & dosage. Antibiotics, Antineoplastic / adverse effects. Carcinoma, Adenosquamous / mortality. Carcinoma, Adenosquamous / pathology. Carcinoma, Adenosquamous / therapy. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Cisplatin / adverse effects. Dose-Response Relationship, Drug. Epirubicin / administration & dosage. Epirubicin / adverse effects. Etoposide / administration & dosage. Etoposide / adverse effects. Female. Follow-Up Studies. Humans. Hysterectomy. Lymphatic Metastasis. Middle Aged. Mitomycin / administration & dosage. Mitomycin / adverse effects. Neoplasm Recurrence, Local. Neoplasm Staging. Pilot Projects. Radiotherapy, Adjuvant. Statistics as Topic. Treatment Outcome. Women's Health

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15162828.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antineoplastic Agents; 3Z8479ZZ5X / Epirubicin; 50SG953SK6 / Mitomycin; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


51. Coupienne I, Piette J, Bontems S: How to monitor NF-kappaB activation after photodynamic therapy. Methods Mol Biol; 2010;635:79-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • For several years, photodynamic therapy (PDT) has emerged as an attractive alternative approach for the treatment of different affections involving various forms of cancer and an increasing number of reports have highlighted the activation of the NF-kappaB following PDT treatment.
  • Furthermore, it has been shown that the mechanism of activation of the NF-kappaB as well as its target genes depends on the nature of the photosensitizers and the cell type used.
  • As a working model we will present results obtained from a 5-aminolevulinic acid-PDT treatment on cervix adenocarcinoma cells.
  • [MeSH-minor] Active Transport, Cell Nucleus / drug effects. Active Transport, Cell Nucleus / radiation effects. Aminolevulinic Acid / pharmacology. Aminolevulinic Acid / therapeutic use. Animals. Base Sequence. Blotting, Western. Cell Nucleus / drug effects. Cell Nucleus / metabolism. Cell Nucleus / radiation effects. Cytoplasm / drug effects. Cytoplasm / metabolism. Cytoplasm / radiation effects. Gene Expression Regulation, Neoplastic / drug effects. Gene Expression Regulation, Neoplastic / radiation effects. Genes, Reporter / genetics. HeLa Cells. Humans. I-kappa B Proteins / metabolism. Luciferases / genetics. Photosensitizing Agents / pharmacology. Photosensitizing Agents / therapeutic use. Synaptotagmin I / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20552341.001).
  • [ISSN] 1940-6029
  • [Journal-full-title] Methods in molecular biology (Clifton, N.J.)
  • [ISO-abbreviation] Methods Mol. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / I-kappa B Proteins; 0 / NF-kappa B; 0 / Photosensitizing Agents; 0 / Synaptotagmin I; 139874-52-5 / NF-kappaB inhibitor alpha; 88755TAZ87 / Aminolevulinic Acid; EC 1.13.12.- / Luciferases
  •  go-up   go-down


52. Ibrahim EM, Stewart RL, Corke K, Blackett AD, Tidy JA, Wells M: Upregulation of CD44 expression by interleukins 1, 4, and 13, transforming growth factor-beta1, estrogen, and progestogen in human cervical adenocarcinoma cell lines. Int J Gynecol Cancer; 2006 Jul-Aug;16(4):1631-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Upregulation of CD44 expression by interleukins 1, 4, and 13, transforming growth factor-beta1, estrogen, and progestogen in human cervical adenocarcinoma cell lines.
  • Although cervical adenocarcinoma constitutes approximately 10-20% of primary malignant tumors of the uterine cervix, its pathogenesis is less well understood than that of the corresponding squamous cancer.
  • CD44 is a cell surface glycoprotein postulated to play a role in many biologic processes including tumor growth and metastasis.
  • It thus has potential as a diagnostic marker and even as a target for therapeutic approaches directed against specific epitopes.
  • The effects of interleukin (IL)-1alpha, IL-1beta, IL-4, IL-13, transforming growth factor (TGF)-beta1, estrogen, and progestogen on CD44v5 expression were examined in cultures of three human cervical adenocarcinoma cell lines (HeLa, HeLa229, and HS588T).
  • [MeSH-major] Adenocarcinoma / metabolism. Antigens, CD44 / metabolism. Estrogens / pharmacology. Interleukins / pharmacology. Progestins / pharmacology. Transforming Growth Factor beta1 / pharmacology. Uterine Cervical Neoplasms / metabolism
  • [MeSH-minor] Blotting, Western. Female. Flow Cytometry. HeLa Cells. Humans. Interleukin-1 / pharmacology. Interleukin-13 / pharmacology. Interleukin-4 / pharmacology. Tumor Cells, Cultured / drug effects. Up-Regulation

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16884377.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD44; 0 / Estrogens; 0 / Interleukin-1; 0 / Interleukin-13; 0 / Interleukins; 0 / Progestins; 0 / TGFB1 protein, human; 0 / Transforming Growth Factor beta1; 207137-56-2 / Interleukin-4
  •  go-up   go-down


53. Gomes CA, da Cruz TG, Andrade JL, Milhazes N, Borges F, Marques MP: Anticancer activity of phenolic acids of natural or synthetic origin: a structure-activity study. J Med Chem; 2003 Dec 4;46(25):5395-401
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anticancer activity of phenolic acids of natural or synthetic origin: a structure-activity study.
  • Several phenolic acids-caffeic and gallic acid derivatives-were synthesized and screened for their potential antiproliferative and cytotoxic properties, in different human cancer cell lines: mammary gland and cervix adenocarcinomas and lymphoblastic leukemia.
  • The selected phenols were structurally related, which allowed us to gather important information regarding the structure-activity relationships underlying the biological activity of such compounds.
  • This is proposed to be due to a balance between the antioxidant and pro-oxidant properties of this kind of agent.
  • Distinct effects were found for different cell lines, which points to a significant specificity of action of the drugs tested.
  • It was verified, for the types of cancer investigated, that the trihydroxylated derivatives yielded better results than the dihydroxylated ones.
  • [MeSH-major] Antineoplastic Agents / chemical synthesis. Caffeic Acids / chemical synthesis. Gallic Acid / analogs & derivatives. Gallic Acid / chemical synthesis. Phenols / chemical synthesis
  • [MeSH-minor] Adenocarcinoma. Breast Neoplasms. Cell Division / drug effects. Cell Line, Tumor. Cell Survival / drug effects. Drug Screening Assays, Antitumor. Female. Humans. Leukemia, Lymphoid. Magnetic Resonance Spectroscopy. Models, Molecular. Molecular Conformation. Spectrometry, Mass, Electrospray Ionization. Spectrophotometry, Ultraviolet. Spectroscopy, Fourier Transform Infrared. Structure-Activity Relationship. Uterine Cervical Neoplasms

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. GALLIC ACID .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14640548.001).
  • [ISSN] 0022-2623
  • [Journal-full-title] Journal of medicinal chemistry
  • [ISO-abbreviation] J. Med. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Caffeic Acids; 0 / Phenols; 632XD903SP / Gallic Acid
  •  go-up   go-down


54. Esteves M, Siquet C, Gaspar A, Rio V, Sousa JB, Reis S, Marques MP, Borges F: Antioxidant versus cytotoxic properties of hydroxycinnamic acid derivatives - a new paradigm in phenolic research. Arch Pharm (Weinheim); 2008 Mar;341(3):164-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These compounds were found to display significant growth inhibition and cytotoxic effects towards a human cervix adenocarcinoma cell line (HeLa).
  • [MeSH-major] Antineoplastic Agents / pharmacology. Coumaric Acids / pharmacology. Free Radical Scavengers / pharmacology
  • [MeSH-minor] Female. Free Radicals / metabolism. HeLa Cells. Humans. Hydrophobic and Hydrophilic Interactions. Liposomes. Oxidative Stress / drug effects. Structure-Activity Relationship. Uterine Cervical Neoplasms / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18275037.001).
  • [ISSN] 0365-6233
  • [Journal-full-title] Archiv der Pharmazie
  • [ISO-abbreviation] Arch. Pharm. (Weinheim)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Coumaric Acids; 0 / Free Radical Scavengers; 0 / Free Radicals; 0 / Liposomes
  •  go-up   go-down


55. Leppäluoto PA: A model of the differentiation and relative incidence of glandular versus squamous cell neoplasia of the uterine cervix: connection between incidence and etiology. Acta Obstet Gynecol Scand; 2008;87(8):800-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A model of the differentiation and relative incidence of glandular versus squamous cell neoplasia of the uterine cervix: connection between incidence and etiology.
  • It has remained unclear why cervical adenocarcinoma, as observed in consecutive screening, has rapidly increased during the past decades, while at the same time both that of squamous cell carcinoma (SCC) and the combined toll of adeno- and SCC have consistently decreased.
  • Frequent alterations in vaginal acidity and changing sexual habits in the era after the oral contraceptive pills and even after the introduction of erectile dysfunction medication, contribute to the pathogenetic scene.
  • [MeSH-major] Adenocarcinoma / etiology. Carcinoma, Squamous Cell / etiology. Uterine Cervical Neoplasms / etiology
  • [MeSH-minor] Contraceptives, Oral, Hormonal. Europe / epidemiology. Female. Humans. Incidence. Models, Biological. Risk Factors. Sexual Behavior


56. Miller B, Dunn J, Dalrymple J, Krivak TC: Pelvic sidewall adenocarcinoma after definitive therapy for cervical adenocarcinoma in situ. Gynecol Oncol; 2005 Nov;99(2):489-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pelvic sidewall adenocarcinoma after definitive therapy for cervical adenocarcinoma in situ.
  • BACKGROUND: Traditionally, hysterectomy is considered definitive therapy for cervical adenocarcinoma in situ (AIS) in women beyond childbearing.
  • CASE: A 45-year-old gravida 2, para 2 patient presented with cervical dysplasia and on pathology review of the large loop excision procedure cervical adenocarcinoma in situ was diagnosed.
  • Final pathology revealed adenocarcinoma in situ with negative margins.
  • A CT-guided biopsy of the mass was consistent with invasive adenocarcinoma of the endocervical type.
  • CONCLUSION: This case depicts another example of the unpredictable nature of cervical AIS.
  • Despite undergoing definitive surgery, a residual focus of disease may remain leading to invasive adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Carcinoma in Situ / surgery. Pelvic Neoplasms / pathology. Uterine Cervical Neoplasms / surgery
  • [MeSH-minor] Female. Humans. Hysterectomy. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / radiotherapy


57. Kundaković T, Stanojković T, Juranić Z, Kovacević N: Cytotoxicity in vitro of naphthazarin derivatives from Onosma arenaria. Phytother Res; 2006 Jul;20(7):602-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The cytotoxicity of naphthazarin derivatives isolated from the roots of Onosma arenaria on human cervix adenocarcinoma cells (HeLa) and leukaemia K562 cells, as well on non-malignant peripheral blood mononuclear cells (PBMC) was studied.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / pharmacology. Boraginaceae / chemistry. Naphthoquinones / chemistry. Naphthoquinones / toxicity
  • [MeSH-minor] Adenocarcinoma / drug therapy. Cell Line, Tumor. Female. Humans. Inhibitory Concentration 50. Leukemia / drug therapy. Leukocytes, Mononuclear / drug effects. Phytohemagglutinins / pharmacology. Phytotherapy. Plant Roots / chemistry. Uterine Cervical Neoplasms / drug therapy

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16718737.001).
  • [ISSN] 0951-418X
  • [Journal-full-title] Phytotherapy research : PTR
  • [ISO-abbreviation] Phytother Res
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Naphthoquinones; 0 / Phytohemagglutinins; 475-38-7 / naphthazarin
  •  go-up   go-down


58. Yamanaka I, Koizumi M, Baba T, Yamashita S, Suzuki T, Kudo R: Epidermal growth factor increased the expression of alpha2beta1-integrin and modulated integrin-mediated signaling in human cervical adenocarcinoma cells. Exp Cell Res; 2003 Jun 10;286(2):165-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidermal growth factor increased the expression of alpha2beta1-integrin and modulated integrin-mediated signaling in human cervical adenocarcinoma cells.
  • We examined the effect of EGF on motility, migration, and morphology of a human adenocarcinoma cell line CAC-1.
  • EGF treatment increased the motility of cervical adenocarcinoma cells and promoted migration of the cells on fibronectin and type IV collagen.
  • A tyrosine kinase inhibitor (ZD1839) blocked EGF-induced changes in cervical adenocarcinoma cells.
  • [MeSH-major] Adenocarcinoma / metabolism. Cell Movement / physiology. Epidermal Growth Factor / metabolism. Integrin alpha2beta1 / metabolism. Receptor, Epidermal Growth Factor / metabolism. Uterine Cervical Neoplasms / metabolism
  • [MeSH-minor] Antibodies / pharmacology. Cell Size / drug effects. Cell Size / physiology. Collagen Type IV / pharmacology. Enzyme Inhibitors / pharmacology. Female. Fibronectins / pharmacology. Focal Adhesion Kinase 1. Focal Adhesion Protein-Tyrosine Kinases. Humans. Phosphorylation / drug effects. Protein-Tyrosine Kinases / drug effects. Protein-Tyrosine Kinases / metabolism. Pseudopodia / drug effects. Pseudopodia / metabolism. Pseudopodia / ultrastructure. Signal Transduction / drug effects. Signal Transduction / physiology. Tumor Cells, Cultured. Tyrosine / metabolism

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • Hazardous Substances Data Bank. L-TYROSINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12749846.001).
  • [ISSN] 0014-4827
  • [Journal-full-title] Experimental cell research
  • [ISO-abbreviation] Exp. Cell Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies; 0 / Collagen Type IV; 0 / Enzyme Inhibitors; 0 / Fibronectins; 0 / Integrin alpha2beta1; 42HK56048U / Tyrosine; 62229-50-9 / Epidermal Growth Factor; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.2 / Focal Adhesion Kinase 1; EC 2.7.10.2 / Focal Adhesion Protein-Tyrosine Kinases; EC 2.7.10.2 / PTK2 protein, human
  •  go-up   go-down


59. Engi H, Vasas A, Rédei D, Molnár J, Hohmann J: New MDR modulators and apoptosis inducers from Euphorbia species. Anticancer Res; 2007 Sep-Oct;27(5A):3451-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Several macrocyclic diterpenes with jatrophane or lathyrane skeletons were isolated from methanol extracts of Hungarian Euphorbia species and evaluated for multidrug resistance (MDR)-reversing activity on a human colon cancer cell line.
  • The capacity of the most effective derivative to induce apoptosis was demonstrated by flow cytometric analysis and by staining with ethidium bromide and acridine orange, using human mdrl gene-transfected mouse lymphoma cells and a human cervical adenocarcinoma cell line.
  • [MeSH-major] Apoptosis / drug effects. Colonic Neoplasms / drug therapy. Diterpenes / pharmacology. Euphorbia / chemistry
  • [MeSH-minor] Acridine Orange. Cell Growth Processes / drug effects. Drug Resistance, Multiple. Drug Resistance, Neoplasm. Ethidium. Humans. Plant Extracts / isolation & purification. Plant Extracts / pharmacology. Staining and Labeling / methods

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17970094.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Diterpenes; 0 / Plant Extracts; EN464416SI / Ethidium; F30N4O6XVV / Acridine Orange
  •  go-up   go-down


60. Fiuza SM, Gomes C, Teixeira LJ, Girão da Cruz MT, Cordeiro MN, Milhazes N, Borges F, Marques MP: Phenolic acid derivatives with potential anticancer properties--a structure-activity relationship study. Part 1: methyl, propyl and octyl esters of caffeic and gallic acids. Bioorg Med Chem; 2004 Jul 1;12(13):3581-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phenolic acid derivatives with potential anticancer properties--a structure-activity relationship study. Part 1: methyl, propyl and octyl esters of caffeic and gallic acids.
  • The antiproliferative and cytotoxic properties of polyphenolic acid derivatives, structurally related with the natural models caffeic and gallic acids, have been tested in human cervix adenocarcinoma cells (HeLa).
  • Marked structure-activity relationships (SARs)--namely the number of hydroxyl ring substituents--were found to rule the biological effect of such systems.
  • [MeSH-major] Antineoplastic Agents / chemistry. Antineoplastic Agents / pharmacology. Caffeic Acids / chemistry. Caffeic Acids / pharmacology. Gallic Acid / chemistry. Gallic Acid / pharmacology. Hydroxybenzoates / pharmacology
  • [MeSH-minor] Cell Line. Cell Survival / drug effects. Drug Screening Assays, Antitumor. Esters / chemistry. Humans. Inhibitory Concentration 50. Methylation. Molecular Structure. Structure-Activity Relationship

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. GALLIC ACID .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15186842.001).
  • [ISSN] 0968-0896
  • [Journal-full-title] Bioorganic & medicinal chemistry
  • [ISO-abbreviation] Bioorg. Med. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Caffeic Acids; 0 / Esters; 0 / Hydroxybenzoates; 29656-58-4 / phenolic acid; 632XD903SP / Gallic Acid
  •  go-up   go-down


61. Li L, Bu S, Bäckström T, Landström M, Ulmsten U, Fu X: Induction of apoptosis and G2/M arrest by 2-methoxyestradiol in human cervical cancer HeLaS3 cells. Anticancer Res; 2004 Mar-Apr;24(2B):873-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Induction of apoptosis and G2/M arrest by 2-methoxyestradiol in human cervical cancer HeLaS3 cells.
  • In the present study, the effects of 2-ME on human cervical cancer HeLaS3 cells and on normal cervical epithelial cells were evaluated.
  • 2-ME treatment resulted in a slight increase of the G2/M population, but no apoptosis, in normal cervical epithelial cells.
  • CONCLUSION: 2-ME induced apoptosis via the iNOS pathway and caused G2/M cell cycle arrest in human cervical cancer HeLaS3 cells, but showed only slight effects on normal cervical epithelial cells.
  • These data suggest that 2-ME might be an adjuvant agent in the treatment of cervical cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Apoptosis / drug effects. Cell Cycle / drug effects. Estradiol / analogs & derivatives. Estradiol / pharmacology. Uterine Cervical Neoplasms / drug therapy
  • [MeSH-minor] Cell Division / drug effects. Cervix Uteri / cytology. Cervix Uteri / drug effects. Epithelial Cells / cytology. Epithelial Cells / drug effects. Female. G2 Phase / drug effects. HeLa Cells. Humans. Mitosis / drug effects


62. Jamal W, Phillips SJ, Hemmings R, Lapensée L, Couturier B, Bissonnette F, Kadoch IJ: Successful pregnancy following novel IVF protocol and transmyometrial embryo transfer after radical vaginal trachelectomy. Reprod Biomed Online; 2009 May;18(5):700-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Radical vaginal trachelectomy in patients with early-stage cervical cancer is an oncologically safe procedure in well-selected patients.
  • Successful pregnancy in a patient with radical vaginal trachelectomy is possible, with two-thirds of pregnancies resulting in live birth.
  • However, it presents a great challenge for assisted reproductive techniques and reproductive medicine in cases with subsequent severe cervical stenosis.
  • This is a report of a 38-year-old patient who underwent radical vaginal trachelectomy at the age of 33 years for early stage (IA2) adenocarcinoma and subsequently presented with infertility due to cervical factors.
  • As it was impossible to perform transcervical embryo transfer with an almost absent severely stenotic cervical opening, a transmyometrial embryo transfer under ultrasound guidance was performed.
  • [MeSH-major] Adenocarcinoma / surgery. Cervix Uteri / surgery. Embryo Transfer / methods. Fertilization in Vitro / methods. Gynecologic Surgical Procedures / methods. Uterine Cervical Neoplasms / surgery

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19549451.001).
  • [ISSN] 1472-6491
  • [Journal-full-title] Reproductive biomedicine online
  • [ISO-abbreviation] Reprod. Biomed. Online
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


63. Kwon HJ, Hong YK, Kim KH, Han CH, Cho SH, Choi JS, Kim BW: Methanolic extract of Pterocarpus santalinus induces apoptosis in HeLa cells. J Ethnopharmacol; 2006 Apr 21;105(1-2):229-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this study, therefore, we report the cytotoxic activity and the mechanism of cell death exhibited by the methanol extract of Ptercarpus santalinus (MEPS) against human cervical adenocarcinoma cell line, HeLa.
  • These results suggest that MEPS exhibits antiproliferative effect on HeLa cells via apoptosis, and it may be a potential candidate in field of anticancer drug discovery.
  • [MeSH-major] Apoptosis / drug effects. Methanol / chemistry. Plant Extracts / pharmacology. Pterocarpus / chemistry
  • [MeSH-minor] Blotting, Western. Caspases / metabolism. Cell Cycle. Cell Division / drug effects. Down-Regulation. Enzyme Activation. HeLa Cells. Humans. Hydrolysis. Poly(ADP-ribose) Polymerases / metabolism

  • Hazardous Substances Data Bank. METHANOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16326057.001).
  • [ISSN] 0378-8741
  • [Journal-full-title] Journal of ethnopharmacology
  • [ISO-abbreviation] J Ethnopharmacol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Plant Extracts; EC 2.4.2.30 / Poly(ADP-ribose) Polymerases; EC 3.4.22.- / Caspases; Y4S76JWI15 / Methanol
  •  go-up   go-down


64. Wang HL, Lu DW: Detection of human papillomavirus DNA and expression of p16, Rb, and p53 proteins in small cell carcinomas of the uterine cervix. Am J Surg Pathol; 2004 Jul;28(7):901-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of human papillomavirus DNA and expression of p16, Rb, and p53 proteins in small cell carcinomas of the uterine cervix.
  • Human papillomavirus (HPV) has been implicated as an etiologic agent for the development of primary small cell carcinoma of the uterine cervix, a rare but highly aggressive malignancy.
  • In squamous cell carcinoma and adenocarcinoma of the cervix, HPV infection is also associated with overexpression of p16, a cyclin-dependent kinase inhibitor.
  • In this study, 22 cases of primary small cell carcinoma of the uterine cervix were subjected to broad-spectrum HPV DNA amplification and typing, and immunohistochemically examined for the expression of p16, Rb, and p53 proteins.
  • The results show that HPV DNA was detected in every case (100%), with 18 cases (82%) harboring type 18.
  • While similar p16 and Rb expression patterns were observed in these HPV-negative tumors, a different expression pattern for p53 was noted where strong nuclear staining was seen in 8 cases (47%; P = 0.0004 compared with cervical tumors).
  • These observations indicate that different mechanisms are involved in the pathogenesis of small cell carcinomas of the uterine cervix and support the notion that nuclear p16 overexpression serves as an indication of Rb defunctioning in tumor cells, which may or may not result from high-risk HPV infection.
  • [MeSH-major] Carcinoma, Small Cell / chemistry. Cyclin-Dependent Kinase Inhibitor p16 / analysis. DNA, Viral / analysis. Papillomaviridae / genetics. Retinoblastoma Protein / analysis. Tumor Suppressor Protein p53 / analysis. Uterine Cervical Neoplasms / chemistry
  • [MeSH-minor] Adenocarcinoma / chemistry. Colorectal Neoplasms / chemistry. Female. Humans. Immunohistochemistry. Papillomavirus Infections / complications. Urinary Bladder Neoplasms / chemistry


65. Banno K, Yanokura M, Kawaguchi M, Kuwabara Y, Akiyoshi J, Kobayashi Y, Iwata T, Hirasawa A, Fujii T, Susumu N, Tsukazaki K, Aoki D: Epigenetic inactivation of the CHFR gene in cervical cancer contributes to sensitivity to taxanes. Int J Oncol; 2007 Oct;31(4):713-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epigenetic inactivation of the CHFR gene in cervical cancer contributes to sensitivity to taxanes.
  • A relationship between inactivation of mitotic checkpoint genes and sensitivity of cancer cells to anticancer agents has been reported.
  • We investigated the effect of epigenetic inactivation by aberrant hypermethylation of the mitotic checkpoint gene CHFR (checkpoint with forkhead and ring finger) on the sensitivity of cervical cancer cells to taxanes.
  • Methylation-specific PCR (MSP) of cervical smears showed aberrant methylation of CHFR in 12.3% (2/14) of adenocarcinoma specimens.
  • In contrast, aberrant DNA methylation was not detected in normal cervical cells or squamous cell carcinoma cells.
  • Aberrant methylation of CHFR was also analyzed in 6 human cervical carcinoma-derived cell lines and was observed in SKG-IIIb and HeLa cells.
  • In conclusion, aberrant methylation of the CHFR gene may be useful as a molecular marker for selection of therapy for patients with cervical adenocarcinoma with a poor prognosis, and may also suggest a new therapeutic strategy of targeting CHFR in cervical cancer.
  • To our knowledge, this study is the first to examine epigenetic inactivation by aberrant hypermethylation of CHFR in cervical cancer.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Bridged Compounds / pharmacology. Cell Cycle Proteins / genetics. Epigenesis, Genetic. Gene Silencing / drug effects. Neoplasm Proteins / genetics. Taxoids / pharmacology. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / genetics
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / genetics. Adenocarcinoma, Mucinous / drug therapy. Adenocarcinoma, Mucinous / genetics. Antimetabolites, Antineoplastic / pharmacology. Azacitidine / pharmacology. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / genetics. DNA Methylation. DNA, Neoplasm / genetics. DNA, Neoplasm / metabolism. Drug Tolerance. Female. Gene Expression Regulation, Neoplastic / drug effects. Humans. Promoter Regions, Genetic / genetics. RNA, Small Interfering / pharmacology. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • Hazardous Substances Data Bank. AZACITIDINE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17786301.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Bridged Compounds; 0 / CHFR protein, human; 0 / Cell Cycle Proteins; 0 / DNA, Neoplasm; 0 / Neoplasm Proteins; 0 / RNA, Small Interfering; 0 / Taxoids; 1605-68-1 / taxane; M801H13NRU / Azacitidine
  •  go-up   go-down


66. Morimura Y, Hashimoto T, Soeda S, Fujimori K, Yamada H, Yanagida K, Sato A: Angiosarcoma of vagina successfully treated with interleukin-2 therapy and chemotherapy: a case report. J Obstet Gynaecol Res; 2001 Aug;27(4):231-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report a case of angiosarcoma of the vagina in a 61-year-old woman who had undergone radical hysterectomy and pelvic irradiation for uterine cervical adenocarcinoma 14 years previously.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hemangiosarcoma / drug therapy. Interleukin-2 / therapeutic use. Vaginal Neoplasms / drug therapy
  • [MeSH-minor] Cyclophosphamide / administration & dosage. Dacarbazine / administration & dosage. Diagnosis, Differential. Doxorubicin / administration & dosage. Drug Administration Schedule. Female. Humans. Hysterectomy. Middle Aged. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Vaginal Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11721736.001).
  • [ISSN] 1341-8076
  • [Journal-full-title] The journal of obstetrics and gynaecology research
  • [ISO-abbreviation] J. Obstet. Gynaecol. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Interleukin-2; 5J49Q6B70F / Vincristine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide
  • [Number-of-references] 19
  •  go-up   go-down


67. Swan SH: Intrauterine exposure to diethylstilbestrol: long-term effects in humans. APMIS; 2000 Dec;108(12):793-804
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Vaginal clear cell adenocarcinoma (CCAC), the most severe consequence of prenatal exposure to DES, affected only 0.1% of exposed females, while the far more prevalent teratogenic and reproductive effects of DES were only discovered when DES daughter were screened for CCAC.
  • Initial studies, conducted before most DES daughters had tried to conceive, examined vaginal cancer and vaginal, cervical and uterine abnormalities.
  • While most DES daughters can eventually experience a live birth, this is less likely in women with genital tract abnormalities, in whom there is a two-thirds chance that each pregnancy will be unsuccessful.
  • [MeSH-major] Diethylstilbestrol / adverse effects. Estrogens, Non-Steroidal / adverse effects. Pregnancy Complications / drug therapy. Prenatal Exposure Delayed Effects
  • [MeSH-minor] Abnormalities, Drug-Induced / epidemiology. Adenocarcinoma, Clear Cell / chemically induced. Administration, Intravaginal. Cervix Uteri / abnormalities. Female. Follow-Up Studies. Gestational Age. Humans. Infant, Newborn. Infant, Newborn, Diseases / chemically induced. Infant, Newborn, Diseases / epidemiology. Male. Pregnancy. Risk. Teratoma / chemically induced. Testicular Neoplasms / chemically induced. United States / epidemiology. Uterus / abnormalities. Vagina / abnormalities. Vaginal Diseases / chemically induced. Vaginal Diseases / epidemiology. Vaginal Neoplasms / chemically induced

  • MedlinePlus Health Information. consumer health - Health Problems in Pregnancy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DIETHYLSTILBESTROL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11252812.001).
  • [ISSN] 0903-4641
  • [Journal-full-title] APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  • [ISO-abbreviation] APMIS
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Estrogens, Non-Steroidal; 731DCA35BT / Diethylstilbestrol
  • [Number-of-references] 75
  •  go-up   go-down


68. Wang SY, Yang KW, Hsu YT, Chang CL, Yang YC: The differential inhibitory effects of genistein on the growth of cervical cancer cells in vitro. Neoplasma; 2001;48(3):227-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The differential inhibitory effects of genistein on the growth of cervical cancer cells in vitro.
  • The biological effect of genistein on cervical cancer was studied on two cervical cancer cell lines with different cellular characteristics.
  • The underlying molecular mechanism was further elucidated by apoptosis analysis and expression levels of cell cycle regulatory proteins.
  • While the underlying mechanism needs to be further studied, the higher suppressive effect on invasion of HeLa cells, an adenocarcinoma cell line, are noteworthy.
  • This in vitro observation may have clinical implication to improve the treatment of cervical adenocarcinoma.
  • [MeSH-major] Cell Cycle / drug effects. Genistein / pharmacology. Growth Inhibitors / pharmacology. Uterine Cervical Neoplasms / drug therapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Blotting, Western. Carcinoma, Squamous Cell / drug therapy. Female. HeLa Cells / drug effects. Humans. Inhibitory Concentration 50. Tumor Cells, Cultured / drug effects

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • Hazardous Substances Data Bank. GENISTEIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11583294.001).
  • [ISSN] 0028-2685
  • [Journal-full-title] Neoplasma
  • [ISO-abbreviation] Neoplasma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Slovakia
  • [Chemical-registry-number] 0 / Growth Inhibitors; DH2M523P0H / Genistein
  •  go-up   go-down


69. Niwa T, Yoshida T, Doiuchi T, Ito K, Nakayama H, Odagiri K, Inoue T: Factors predicting tumour regression in locally advanced cervical adenocarcinoma treated with balloon-occluded intra-arterial chemotherapy. Br J Radiol; 2008 Aug;81(968):659-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Factors predicting tumour regression in locally advanced cervical adenocarcinoma treated with balloon-occluded intra-arterial chemotherapy.
  • We retrospectively assessed the factors that may impede tumour reduction of locally advanced cervical adenocarcinoma treated with balloon-occluded arterial infusion chemotherapy (BOAI) as initial therapy.
  • BOAI was performed via uterine arteries in 21 patients, and via the anterior division or main trunk of the internal iliac artery (when the uterine arteries were obscured) in 10 patients.
  • Factors including the patient's age, tumour stage (using the International Federation of Gynecology and Obstetrics classification), the artery used for infusion, infused drug, presence of intravenous systemic chemotherapy, initial tumour size, tumour volume and presence of lymph node metastases were assessed for their ability to predict tumour response to BOAI using univariate and multivariate analyses.
  • Internal iliac arterial infusion significantly correlated with "no response" compared with uterine arterial infusion (p<0.001).
  • These data suggest that uterine arteries being obscured to arterial infusion may be associated with a poor response to BOAI for cervical adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / drug therapy. Uterine Cervical Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Analysis of Variance. Antineoplastic Agents / administration & dosage. Antineoplastic Agents, Alkylating / administration & dosage. Catheterization / methods. Cisplatin / administration & dosage. Cyclophosphamide / administration & dosage. Female. Humans. Infusions, Intra-Arterial / methods. Magnetic Resonance Imaging. Middle Aged. Prognosis. Remission Induction. Retrospective Studies. Risk Factors. Uterus / blood supply

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18628334.001).
  • [ISSN] 1748-880X
  • [Journal-full-title] The British journal of radiology
  • [ISO-abbreviation] Br J Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Alkylating; 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


70. Kos M, Sarkanj-Golub R, Cupić H, Balicević D: [The correlation of inflammation and epithelial changes in the Pap smears of cervix uteri]. Acta Med Croatica; 2005;59(4):297-302
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The correlation of inflammation and epithelial changes in the Pap smears of cervix uteri].
  • A modification of The Bethesda System classification of cytologic findings of uterine cervix named Zagreb 1990 has been accepted in Croatia as a unique classification, the use of which has begun after the publication and printing of the new, uniform method of cytologic examination.
  • AIM: The aim of this study was to assess the number and type of cytologic abnormalities of uterine cervix classified according to Zagreb 1990, on routinely examined Pap smears during the 6-year period, and to investigate the connection of these abnormalities with lower genital tract infections.
  • A total of 59901 Pap smears (patients aged 17-79) were routinely examined: the cytopathologic diagnosis of CIN I or higher recorded in 3664 (6.12%) of them.
  • Endocervical adenocarcinoma was cytologically diagnosed in only 0.0055% of all Pap smears examined.
  • Of specific causative agents HPV and Chlamydia trachomatis were significantly more frequently found in the group with epithelial dysplasia/carcinoma than in the control group (p < 0.05 both), however, Gardnerella vaginalis, Trichomonas vaginalis or Candida yielded no significant differences.
  • It is concluded that inflammation very likely contributes to the development of precancerous lesions of the cervix, HPV and Chlamydia showing strongest correlation, at least in a part of our population.
  • [MeSH-major] Cervix Uteri / pathology. Papanicolaou Test. Uterine Cervical Neoplasms / diagnosis. Vaginal Smears
  • [MeSH-minor] Adolescent. Adult. Aged. Epithelium / pathology. Female. Humans. Infection / complications. Infection / diagnosis. Inflammation. Middle Aged. Uterine Cervical Diseases / complications. Uterine Cervical Diseases / microbiology


71. van den Brûle FA, Clausse N, Delvenne P, Franzen-Detrooz E, Castronovo V: Combined interferon-gamma and tumor necrosis factor-alpha treatment differentially affects adhesion and migration of keratinocyte-derived cells to laminin-1. Cell Adhes Commun; 2000 Jan;7(4):321-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Interactions with the extracellular matrix constitute basic steps in cervix carcinoma cell invasion.
  • In this study, we examined the adhesion and migration profiles of two human papillomavirus (HPV) DNA-transfected keratinocyte-derived cell lines, EIL8 and 18-11S3, and of the cervix adenocarcinoma SiHa cell line, towards laminin-1, and the selective effect of a 24-72 h treatment of 1000 U/ml interferon-gamma (IFN-gamma) and tumor necrosis factor-alpha (TNF-alpha), a treatment that significantly decreases cervix carcinoma cell proliferation and progression in nude mice, on these parameters.
  • Compared to normal cervix keratinocytes (CK) and two HPV DNA-transfected keratinocyte cell lines, in basal conditions, the SiHa cell line was characterized by increased attachment (SiHa, 48.74 +/- 4.02 vs. normal keratinocytes, 4.32 +/- 0.40, EIL8, 17.80 +/- 3.03 and 18-11S3, 17.82 +/- 1.48% of attached cells after 30 min) and marked directed chemotactic migration towards laminin-1.
  • Interestingly, treatment of the cells with the cytokines (1000 U/ml IFN-gamma and TNF-alpha) did not modulate the adhesion properties of the cells, but chemotactic migration of SiHa cells to laminin-1 was significantly decreased, while migration towards type I collagen was increased.
  • Similar results were obtained with the Ca Ski cervix carcinoma cell line.
  • Our results emphasize the altered pattern of interactions of cervix carcinoma cells with extracellular matrix components such as laminin-1, compared to normal and pre-neoplastic cells, and contributes to the understanding of the effects of cytokine treatment on cervix carcinoma cells.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Cell Movement / drug effects. Interferon-gamma / pharmacology. Keratinocytes / cytology. Laminin / pharmacology. Tumor Necrosis Factor-alpha / pharmacology
  • [MeSH-minor] Adenocarcinoma. Cell Adhesion / drug effects. Cell Division / drug effects. Chemotaxis / drug effects. Collagen / pharmacology. Female. Humans. Neoplasm Invasiveness. Transfection. Tumor Cells, Cultured / cytology. Tumor Cells, Cultured / drug effects. Uterine Cervical Neoplasms

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10714393.001).
  • [ISSN] 1061-5385
  • [Journal-full-title] Cell adhesion and communication
  • [ISO-abbreviation] Cell Adhes. Commun.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] SWITZERLAND
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Laminin; 0 / Tumor Necrosis Factor-alpha; 82115-62-6 / Interferon-gamma; 9007-34-5 / Collagen
  •  go-up   go-down


72. Abadi MA, Barakat RR, Saigo PE: Effects of tamoxifen on cervicovaginal smears from patients with breast cancer. Acta Cytol; 2000 Mar-Apr;44(2):141-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of tamoxifen on cervicovaginal smears from patients with breast cancer.
  • STUDY DESIGN: A group of 48 women with prior breast cancer were divided into three groups: A, tamoxifen-treated patients who developed endometrial carcinoma (n = 20); B, patients with endometrial cancer not treated with tamoxifen (n = 22); and C, tamoxifen-treated patients with no endometrial carcinoma (n = 16).
  • A total of 114 cervicovaginal smears from these patients were evaluated for maturation index, histiocytes, benign and malignant endometrial cells, reactive cellular changes and microorganisms.
  • The number of cases with endometrial cells was significantly higher in smears of treated patients who developed endometrial cancer (A) as compared to groups B and C (P = .01 and .02, respectively).
  • CONCLUSION: Patients treated with tamoxifen exhibited a partial estrogenic effect in their smears regardless of whether they developed endometrial cancer.
  • However, the presence of endometrial cells in the smears indicated a higher risk of endometrial adenocarcinoma.
  • [MeSH-major] Breast Neoplasms / drug therapy. Carcinoma, Endometrioid / chemically induced. Cervix Uteri / drug effects. Endometrial Neoplasms / chemically induced. Estrogen Antagonists / adverse effects. Tamoxifen / adverse effects
  • [MeSH-minor] Aged. Antineoplastic Agents, Hormonal / adverse effects. Epithelial Cells / drug effects. Epithelial Cells / pathology. Female. Humans. Middle Aged. Mitotic Index / drug effects. Vaginal Smears


73. Torres MA, Jhingran A, Thames HD Jr, Levenback CF, Bodurka DC, Ramondetta LM, Eifel PJ: Concurrent chemoradiation in the routine management of patients with cervical cancer: does marital status matter? Int J Gynecol Cancer; 2009 Aug;19(6):1107-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concurrent chemoradiation in the routine management of patients with cervical cancer: does marital status matter?
  • OBJECTIVE: The aim of this study was to investigate the relationship between marital status and outcome in women treated with concurrent chemoradiation (CT-RT) for locally advanced cervical cancer.
  • METHODS: We reviewed the records of all women who received CT-RT for squamous or adenocarcinomas of the cervix at the M. D.
  • Anderson Cancer Center between 1998 and 2005.
  • RESULTS: The SPs were more likely to be African American (P < 0.001), be medically indigent (P < 0.001), and have used illicit drugs (P = 0.01).
  • The SPs more often presented with tumors of 6.0 cm or more (P = 0.01) and stage II to IVA disease (P = 0.02).
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / radiotherapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Marital Status. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / radiotherapy
  • [MeSH-minor] Aged. Aged, 80 and over. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / psychology. Carcinoma, Squamous Cell / radiotherapy. Combined Modality Therapy. Disease Progression. Female. Humans. Middle Aged. Prognosis. Radiotherapy, Adjuvant. Retrospective Studies. Social Class. Treatment Outcome


74. Ota S, Sugiyama T, Ushijima K, Fujiyoshi K, Komai K, Hirai N, Nishida T, Kamura T: Remission of metastatic cervical adenocarcinoma with weekly paclitaxel. Int J Gynecol Cancer; 2001 Mar-Apr;11(2):167-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Remission of metastatic cervical adenocarcinoma with weekly paclitaxel.
  • We report the use of paclitaxel in the successful treatment of a patient with recurrent adenocarcinoma of the cervix.
  • Paclitaxel, 70 mg/m2 by 1-h infusion weekly, was administered to a 59-year-old patient with cervical adenocarcinoma showing lung metastasis.
  • Weekly paclitaxel was very well tolerated, yet was effective for recurrent cervical adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Antineoplastic Agents, Phytogenic / therapeutic use. Lung Neoplasms / secondary. Paclitaxel / therapeutic use. Uterine Cervical Neoplasms / drug therapy
  • [MeSH-minor] Drug Administration Schedule. Female. Humans. Middle Aged. Neoplasm Recurrence, Local / drug therapy

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11328417.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


75. Qin J, Jo YS, Ihm JE, Kim DK, Muhammed M: Thermosensitive nanospheres with a gold layer revealed as low-cytotoxic drug vehicles. Langmuir; 2005 Sep 27;21(20):9346-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thermosensitive nanospheres with a gold layer revealed as low-cytotoxic drug vehicles.
  • These cytotoxicity tests were performed with human cervical adenocarcinoma cells (HeLa cell line) and transformed African green monkey kidney fibroblast cells (Cos-7 cell line).
  • To fabricate the nanostructures as drug vehicles, first, poly(l,l-lactide-co-ethylene glycol) (PLLA-PEG) and poly(N-isopropylacrylamide-co-D,D-lactide) (PNIPAAm-PDLA) were synthesized, and then two kinds of thermosensitive nanospheres comprising "shell-in-shell" structures without a gold layer (PLLA-PEG@PNIPAAm-PDLA) and with a gold layer (Au@PLLA-PEG@PNIPAAm-PDLA) were constructed by a modified double-emulsion method (MDEM).
  • [MeSH-major] Acrylamides / chemistry. Drug Carriers / chemistry. Gold / chemistry. Lactates / chemistry. Polyethylene Glycols / chemistry
  • [MeSH-minor] Animals. Antineoplastic Agents / administration & dosage. Biological Transport / drug effects. COS Cells / drug effects. Calorimetry, Differential Scanning. Cell Survival / drug effects. Cercopithecus aethiops. Female. HeLa Cells / drug effects. Humans. Male. Serum Albumin, Bovine / chemistry. Solubility. Spectrophotometry, Ultraviolet. Temperature. Time Factors. Uterine Cervical Neoplasms / pathology

  • Hazardous Substances Data Bank. GOLD, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16171372.001).
  • [ISSN] 0743-7463
  • [Journal-full-title] Langmuir : the ACS journal of surfaces and colloids
  • [ISO-abbreviation] Langmuir
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Acrylamides; 0 / Antineoplastic Agents; 0 / Drug Carriers; 0 / Lactates; 0 / Serum Albumin, Bovine; 0 / poly(N-isopropylacrylamide-b-lactide); 0 / poly(lactic acid-ethylene glycol); 30IQX730WE / Polyethylene Glycols; 7440-57-5 / Gold
  •  go-up   go-down


76. Sales KJ, Katz AA, Howard B, Soeters RP, Millar RP, Jabbour HN: Cyclooxygenase-1 is up-regulated in cervical carcinomas: autocrine/paracrine regulation of cyclooxygenase-2, prostaglandin e receptors, and angiogenic factors by cyclooxygenase-1. Cancer Res; 2002 Jan 15;62(2):424-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cyclooxygenase-1 is up-regulated in cervical carcinomas: autocrine/paracrine regulation of cyclooxygenase-2, prostaglandin e receptors, and angiogenic factors by cyclooxygenase-1.
  • This study was designed to investigate the expression and molecular signaling of cyclooxygenase-1 (COX-1) in cervical carcinomas.
  • Real-time quantitative reverse transcription-polymerase chain reaction and Western blot analysis confirmed enhanced expression of COX-1 RNA, and protein in squamous cell carcinomas and adenocarcinoma of the cervix.
  • The site of COX-1 expression was localized by immunohistochemistry to the neoplastic epithelial cells in all squamous cell carcinomas and adenocarcinomas studied.
  • Minimal COX-1 immunoreactivity was detected in normal cervix.
  • To explore events associated with COX-1 up-regulation, we developed a doxycycline-regulated expression system in HeLa (cervical carcinoma) cells.
  • Indomethacin, but not NS-398, treatment abolished the up-regulation of expression of COX-2 and PGES in HeLa cells, suggesting that the observed up-regulation of COX-2 and PGES was mediated by COX-1-enzyme products.
  • These data indicate that COX-1 up-regulation modulates the expression of factors that may act in an autocrine/paracrine manner to enhance and sustain tumorigenesis in neoplastic cervical epithelial cells.
  • It is likely that similar mechanisms may act in vivo to modulate tumorigenesis of cervical carcinomas.
  • [MeSH-major] Angiogenesis Inducing Agents / biosynthesis. Isoenzymes / biosynthesis. Prostaglandin-Endoperoxide Synthases / biosynthesis. Receptors, Prostaglandin E / biosynthesis. Uterine Cervical Neoplasms / enzymology
  • [MeSH-minor] Adenocarcinoma / enzymology. Adenocarcinoma / genetics. Carcinoma, Squamous Cell / enzymology. Carcinoma, Squamous Cell / genetics. Cervix Uteri / enzymology. Cyclic AMP / biosynthesis. Cyclooxygenase 1. Cyclooxygenase 2. Dinoprostone / pharmacology. Endothelial Growth Factors / biosynthesis. Epithelial Cells / enzymology. Female. Fibroblast Growth Factor 2 / biosynthesis. Gene Expression Regulation, Enzymologic / drug effects. Gene Expression Regulation, Neoplastic / drug effects. HeLa Cells. Humans. Intramolecular Oxidoreductases / biosynthesis. Lymphokines / biosynthesis. Membrane Proteins. Prostaglandin-E Synthases. Reverse Transcriptase Polymerase Chain Reaction. Up-Regulation / drug effects. Vascular Endothelial Growth Factor A. Vascular Endothelial Growth Factors

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Circ Res. 1998 Aug 10;83(3):233-40 [9710115.001]
  • [Cites] Cancer Res. 1998 Nov 15;58(22):4997-5001 [9823297.001]
  • [Cites] Lab Invest. 1999 Feb;79(2):213-23 [10068209.001]
  • [Cites] Cancer Res. 1999 Mar 1;59(5):987-90 [10070951.001]
  • [Cites] Am J Obstet Gynecol. 1999 Mar;180(3 Pt 1):614-20 [10076137.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Jun 22;96(13):7220-5 [10377395.001]
  • [Cites] Biochem Biophys Res Commun. 1999 Oct 14;264(1):133-8 [10527853.001]
  • [Cites] Nat Med. 1999 Dec;5(12):1418-23 [10581086.001]
  • [Cites] Gynecol Oncol. 2000 Mar;76(3):320-5 [10684704.001]
  • [Cites] Carcinogenesis. 2000 Apr;21(4):543-50 [10753183.001]
  • [Cites] FEBS Lett. 2000 Apr 7;471(1):78-82 [10760517.001]
  • [Cites] J Lipid Res. 2000 Jun;41(6):873-81 [10828079.001]
  • [Cites] J Clin Invest. 2000 Jun;105(11):1589-94 [10841517.001]
  • [Cites] Carcinogenesis. 2000 Sep;21(9):1745-51 [10964107.001]
  • [Cites] Annu Rev Biochem. 2000;69:145-82 [10966456.001]
  • [Cites] Urology. 2000 Oct 1;56(4):671-6 [11018637.001]
  • [Cites] J Biol Chem. 2000 Oct 20;275(42):32783-92 [10869354.001]
  • [Cites] Clin Cancer Res. 2001 Feb;7(2):429-34 [11234900.001]
  • [Cites] J Clin Endocrinol Metab. 2001 May;86(5):2243-9 [11344234.001]
  • [Cites] J Biol Chem. 2001 May 25;276(21):18075-81 [11278548.001]
  • [Cites] Prostaglandins Leukot Essent Fatty Acids. 1989 Sep;37(3):187-91 [2608697.001]
  • [Cites] Biochim Biophys Acta. 1991 May 8;1083(2):121-34 [1903657.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Jun 15;89(12):5547-51 [1319065.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Aug 15;89(16):7384-8 [1380156.001]
  • [Cites] Cancer Res. 1992 Oct 15;52(20):5575-89 [1394181.001]
  • [Cites] Biochem Biophys Res Commun. 1993 Apr 30;192(2):787-93 [8484784.001]
  • [Cites] J Clin Invest. 1994 May;93(5):2230-5 [8182155.001]
  • [Cites] Gastroenterology. 1994 Oct;107(4):1183-8 [7926468.001]
  • [Cites] Mol Pharmacol. 1994 Sep;46(3):477-84 [7935328.001]
  • [Cites] Pharmacol Rev. 1994 Jun;46(2):205-29 [7938166.001]
  • [Cites] Exp Cell Res. 1994 Nov;215(1):137-44 [7525323.001]
  • [Cites] Cancer Metastasis Rev. 1994 Dec;13(3-4):241-56 [7712587.001]
  • [Cites] Cancer Res. 1995 Jun 15;55(12):2556-9 [7780968.001]
  • [Cites] Cell. 1995 Nov 3;83(3):493-501 [8521479.001]
  • [Cites] Biochim Biophys Acta. 1996 Jan 5;1299(1):125-40 [8555245.001]
  • [Cites] Nature. 1996 Apr 4;380(6573):435-9 [8602241.001]
  • [Cites] Gastroenterology. 1996 Apr;110(4):1259-62 [8613017.001]
  • [Cites] J Bone Miner Res. 1996 Oct;11(10):1413-8 [8889840.001]
  • [Cites] Biochem Biophys Res Commun. 1997 Jan 3;230(1):110-4 [9020023.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Apr 1;94(7):3336-40 [9096394.001]
  • [Cites] Cancer Res. 1997 May 1;57(9):1625-9 [9134996.001]
  • [Cites] Science. 1997 Jul 4;277(5322):55-60 [9204896.001]
  • [Cites] Biochem Pharmacol. 1997 Jun 1;53(11):1757-9 [9264330.001]
  • [Cites] J Biol Chem. 1997 Aug 22;272(34):21455-60 [9261162.001]
  • [Cites] Biochem Pharmacol. 1998 Feb 1;55(3):239-46 [9484788.001]
  • [Cites] J Immunol. 1998 Mar 15;160(6):2974-82 [9510202.001]
  • [Cites] J Natl Cancer Inst. 1998 Mar 18;90(6):455-60 [9521170.001]
  • [Cites] Curr Biol. 1998 Apr 23;8(9):529-32 [9560344.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 1998;38:97-120 [9597150.001]
  • [Cites] Life Sci. 1998;62(24):2195-201 [9627078.001]
  • [Cites] Cell. 1998 May 29;93(5):705-16 [9630216.001]
  • [ErratumIn] Cancer Res 2002 Mar 1;62(5):1579. Soeters Roggert P [corrected to Soeters Robbert P]
  • (PMID = 11809691.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / MC/ U127684438; United Kingdom / Medical Research Council / / U.1276.00.004.00002.01/2(61014)
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inducing Agents; 0 / Endothelial Growth Factors; 0 / Isoenzymes; 0 / Lymphokines; 0 / Membrane Proteins; 0 / Receptors, Prostaglandin E; 0 / Vascular Endothelial Growth Factor A; 0 / Vascular Endothelial Growth Factors; 103107-01-3 / Fibroblast Growth Factor 2; E0399OZS9N / Cyclic AMP; EC 1.14.99.1 / Cyclooxygenase 1; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS1 protein, human; EC 1.14.99.1 / PTGS2 protein, human; EC 1.14.99.1 / Prostaglandin-Endoperoxide Synthases; EC 5.3.- / Intramolecular Oxidoreductases; EC 5.3.99.3 / Prostaglandin-E Synthases; K7Q1JQR04M / Dinoprostone
  • [Other-IDs] NLM/ PMC2694304; NLM/ UKMS2451
  •  go-up   go-down


77. Othumpangat S, Kashon M, Joseph P: Sodium arsenite-induced inhibition of eukaryotic translation initiation factor 4E (eIF4E) results in cytotoxicity and cell death. Mol Cell Biochem; 2005 Nov;279(1-2):123-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Exposure to arsenic (As) is a risk factor for the development of diabetes, vascular diseases and cancer.
  • We have also investigated the potential cellular mechanisms underlying the As-induced de-regulation of expression of eIF4E that are most likely responsible for the cytotoxicity and cell death induced by As.
  • Exposure of four different human cell lines - HCT15 (colorectal adenocarcinoma), PLC/PR/5 (hepatocellular carcinoma), HeLa (cervical adenocarcinoma) and Chang (likely derived from HeLa cells) to sodium arsenite (NaAsO2) for time intervals up to 24 h resulted in a concentration-dependent cytotoxicity and cell death.
  • Additional studies conducted to understand the potential mechanisms responsible for NaAsO2-induced inhibition of eIF4E gene expression demonstrated that exposure to NaAsO2 resulted in transcriptional down-regulation of the eIF4E gene only in HCT-15 and HeLa cells, while in the NaAsO2-treated and PLC/PR/5 and Chang cells, the eIF4E mRNA expression level was comparable to those of the corresponding control cells.
  • [MeSH-minor] Animals. CHO Cells. Cell Survival / drug effects. Cricetinae. Cricetulus. Cyclin D1 / genetics. Cyclin D1 / metabolism. Dose-Response Relationship, Drug. Down-Regulation. Gene Expression Regulation / drug effects. HeLa Cells. Humans. RNA Interference. RNA, Messenger / metabolism. RNA, Small Interfering / genetics. RNA, Small Interfering / metabolism. Transfection. Ubiquitin / metabolism

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Environ Health Perspect. 1999 Jul;107(7):593-7 [10379007.001]
  • [Cites] Cell Cycle. 2003 Jul-Aug;2(4):358-68 [12851490.001]
  • [Cites] Toxicol Appl Pharmacol. 2001 May 1;172(3):225-32 [11312651.001]
  • [Cites] Mutat Res. 2003 Jan 10;534(1-2):133-43 [12504762.001]
  • [Cites] Cancer Res. 2000 Jul 1;60(13):3445-53 [10910055.001]
  • [Cites] Mol Cell Biol. 1988 Aug;8(8):3556-9 [3062383.001]
  • [Cites] Annu Rev Biochem. 1998;67:425-79 [9759494.001]
  • [Cites] J Cell Physiol. 2002 Jan;190(1):29-37 [11807808.001]
  • [Cites] J Biol Chem. 2004 Aug 6;279(32):33968-75 [15178684.001]
  • [Cites] J Biol Chem. 1995 Sep 8;270(36):21176-80 [7673150.001]
  • [Cites] Oncogene. 1999 Jul 29;18(30):4326-35 [10439040.001]
  • [Cites] J Toxicol Environ Health A. 2000 Jan 28;59(2):119-34 [10653439.001]
  • [Cites] J Cell Mol Med. 2001 Jul-Sep;5(3):221-39 [12067482.001]
  • [Cites] Mutat Res. 1997 Jun;386(3):219-28 [9219560.001]
  • [Cites] Cancer Res. 2004 Dec 15;64(24):8960-7 [15604259.001]
  • [Cites] Eur J Biochem. 2000 Feb;267(4):1083-91 [10672017.001]
  • [Cites] J Environ Pathol Toxicol Oncol. 2000;19(3):281-6 [10983894.001]
  • [Cites] Science. 1988 Jul 1;241(4861):79-81 [3388020.001]
  • [Cites] Toxicol Appl Pharmacol. 2003 Jan 15;186(2):101-9 [12639501.001]
  • [Cites] J Biol Chem. 2000 Aug 11;275(32):24776-80 [10811643.001]
  • [Cites] Oncogene. 2000 Jun 15;19(26):3021-31 [10871854.001]
  • [Cites] J Biol Chem. 2005 Jul 1;280(26):25162-9 [15878868.001]
  • [Cites] Mol Cell Biol. 1991 Nov;11(11):5435-45 [1922056.001]
  • [Cites] Cancer Causes Control. 1997 May;8(3):371-85 [9498900.001]
  • [Cites] Cell Death Differ. 2001 Aug;8(8):841-9 [11526437.001]
  • [Cites] Cancer Res. 1995 Mar 15;55(6):1296-300 [7882325.001]
  • [Cites] Br J Cancer. 1992 Nov;66(5):888-92 [1419632.001]
  • [Cites] Toxicol Lett. 2002 Jul 7;133(1):47-57 [12076509.001]
  • [Cites] J Biol Chem. 2001 Apr 6;276(14):11414-9 [11150309.001]
  • [Cites] Environ Health Perspect. 2000 May;108(5):393-7 [10811564.001]
  • [Cites] Am J Epidemiol. 1998 Apr 1;147(7):660-9 [9554605.001]
  • [Cites] Oncogene. 2000 Mar 9;19(11):1437-47 [10723135.001]
  • [Cites] J Biol Chem. 1985 May 10;260(9):5486-92 [3988764.001]
  • [Cites] Cancer Res. 2003 Nov 15;63(22):7950-8 [14633726.001]
  • [Cites] Toxicol Lett. 2001 Jul 6;122(3):223-34 [11489357.001]
  • [Cites] Carcinogenesis. 1985 Oct;6(10):1421-6 [3840060.001]
  • [Cites] J Toxicol Environ Health B Crit Rev. 1998 Jul-Sep;1(3):199-241 [9644328.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Nov;87(21):8212-6 [2122455.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Feb 6;93(3):1065-70 [8577715.001]
  • [Cites] Anal Chem. 1999 Apr 1;71(7):1408-14 [10204040.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Feb 19;99(4):1990-5 [11842186.001]
  • [Cites] J Biol Chem. 2001 Aug 3;276(31):29111-5 [11408474.001]
  • [Cites] EMBO J. 1996 Nov 15;15(22):6269-79 [8947050.001]
  • [Cites] Mol Cell Biol. 1996 Nov;16(11):6573-81 [8887686.001]
  • [Cites] Mol Cell Biol. 2002 Mar;22(6):1656-63 [11865045.001]
  • [Cites] Nucleic Acids Res. 1989 Aug 11;17(15):5923-31 [2671936.001]
  • (PMID = 16283521.001).
  • [ISSN] 0300-8177
  • [Journal-full-title] Molecular and cellular biochemistry
  • [ISO-abbreviation] Mol. Cell. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Arsenites; 0 / Eukaryotic Initiation Factor-4E; 0 / RNA, Messenger; 0 / RNA, Small Interfering; 0 / Sodium Compounds; 0 / Ubiquitin; 136601-57-5 / Cyclin D1; 48OVY2OC72 / sodium arsenite
  •  go-up   go-down


78. Kassi E, Papoutsi Z, Fokialakis N, Messari I, Mitakou S, Moutsatsou P: Greek plant extracts exhibit selective estrogen receptor modulator (SERM)-like properties. J Agric Food Chem; 2004 Nov 17;52(23):6956-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To prevent bone loss that occurs with increasing age, nutritional and pharmacological factors are needed.
  • Traditional therapeutic agents (selective estrogen receptor modulators or SERMs, biphosphonates, calcitonin) may have serious side effects or contraindications.
  • In an attempt to find food components potentially acting as SERMs, we submitted four plant aqueous extracts derived from Greek flora (Sideritis euboea, Sideritis clandestina, Marticaria chamomilla, and Pimpinella anisum) in a series of in vitro biological assays reflective of SERM profile.
  • We examined their ability (a) to stimulate the differentiation and mineralization of osteoblastic cell culture by histochemical staining for alkaline phosphatase and Alizarin Red-S staining, (b) to induce, like antiestrogens, the insulin growth factor binding protein 3 (IGFBP3) in MCF-7 breast cancer cells, and (c) to proliferate cervical adenocarcinoma (HeLa) cells by use of MTT assay.
  • Our data reveal that all the plant extracts studied at a concentration range 10-100 microg/mL stimulate osteoblastic cell differentiation and exhibit antiestrogenic effect on breast cancer cells without proliferative effects on cervical adenocarcinoma cells.
  • [MeSH-minor] Breast Neoplasms / metabolism. Calcification, Physiologic / drug effects. Cell Differentiation / drug effects. Cell Division / drug effects. Cell Line. Greece. HeLa Cells. Humans. Insulin-Like Growth Factor Binding Protein 3 / biosynthesis. Matricaria / chemistry. Osteoblasts / drug effects. Pimpinella / chemistry. Sideritis / chemistry. Tumor Cells, Cultured

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15537303.001).
  • [ISSN] 0021-8561
  • [Journal-full-title] Journal of agricultural and food chemistry
  • [ISO-abbreviation] J. Agric. Food Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Insulin-Like Growth Factor Binding Protein 3; 0 / Plant Extracts; 0 / Selective Estrogen Receptor Modulators
  •  go-up   go-down


79. Noguchi M, Yokoyama M, Watanabe S, Uchiyama M, Nakao Y, Hara K, Iwasaka T: Inhibitory effect of the tea polyphenol, (-)-epigallocatechin gallate, on growth of cervical adenocarcinoma cell lines. Cancer Lett; 2006 Mar 28;234(2):135-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibitory effect of the tea polyphenol, (-)-epigallocatechin gallate, on growth of cervical adenocarcinoma cell lines.
  • To investigate the effect of (-)-epigallocatechin gallate (EGCG) on cervical adenocarcinoma, we performed a cell proliferation assay.
  • TRAP assay is used for telomerase activity, flow cytometry analysis and pKi-67 immunofluoroscein staining in cervical adenocarcinoma cell lines (OMC-4, TMCC-1).
  • Our data suggest that EGCG may be effective for the treatment of cervical adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / drug therapy. Catechin / analogs & derivatives. Cell Proliferation / drug effects. Tea / chemistry. Uterine Cervical Neoplasms / drug therapy
  • [MeSH-minor] Apoptosis / drug effects. Cell Line, Tumor. Female. Flavonoids. Flow Cytometry. Humans. Ki-67 Antigen. Phenols. Polyphenols. Telomerase / biosynthesis. Telomerase / drug effects

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15907368.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Flavonoids; 0 / Ki-67 Antigen; 0 / Phenols; 0 / Polyphenols; 0 / Tea; 8R1V1STN48 / Catechin; BQM438CTEL / epigallocatechin gallate; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


80. Bese T, Simsek Y, Bese N, Ilvan S, Arvas M: Extensive pelvic endometriosis with malignant change in tamoxifen-treated postmenopausal women. Int J Gynecol Cancer; 2003 May-Jun;13(3):376-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 74-year-old woman with a history of breast carcinoma who received tamoxifen therapy for 2 years was admitted with uterine bleeding.
  • The cervix, rectum, and the accompanying mass were resected.
  • Histopathologic examination revealed endocervical adenocarcinoma and endometriosis involving cervix uteri and the rectal muscular wall.
  • The patient had two normal cervical smears within the last 3 years and no abnormal appearance was detected within the cervical canal in the hysteroscopic examination.
  • As cervical cancer occurred in a short period, it might be speculated that tamoxifen might have stimulated the proliferative and mitotic activity of cervical endometrial tissue which has progressed into invasive cancer in time.
  • [MeSH-major] Adenocarcinoma / chemically induced. Adnexal Diseases / complications. Antineoplastic Agents, Hormonal / adverse effects. Cell Transformation, Neoplastic / chemically induced. Endometriosis / complications. Tamoxifen / adverse effects. Uterine Cervical Neoplasms / chemically induced
  • [MeSH-minor] Aged. Breast Neoplasms / drug therapy. Female. Gynecologic Surgical Procedures / methods. Humans. Pelvis. Postmenopause


81. Urakami T, Sakai K, Asai T, Fukumoto D, Tsukada H, Oku N: Evaluation of O-[(18)F]fluoromethyl-D-tyrosine as a radiotracer for tumor imaging with positron emission tomography. Nucl Med Biol; 2009 Apr;36(3):295-303
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of O-[(18)F]fluoromethyl-D-tyrosine as a radiotracer for tumor imaging with positron emission tomography.
  • O-[(18)F]Fluoromethyl-D-tyrosine (D-[(18)F]FMT) has been reported as a potential tumor-detecting agent for positron emission tomography (PET).
  • The stereo-selective uptake and release of enantiomerically pure D- and L-[(18)F]FMT by rat C6 glioma cells and human cervix adenocarcinoma HeLa cells were examined.
  • The results of a competitive inhibition study using various amino acids and a selective inhibitor for transport system L suggested that D-[(18)F]FMT, as well as L-[(18)F]FMT, was transported via system L, the large neutral amino acid transporter, possibly via LAT1.
  • In vivo PET imaging of D-[(18)F]FMT in mouse xenograft and rat allograft tumor models showed high contrast with a low background, especially in the abdominal and brain region.
  • D-[(18)F]FMT, however, provides a better tumor-to-background contrast with a tumor/background (contralateral region) ratio of 2.741 vs. 1.878 with the L-isomer, whose difference appears to be caused by a difference in the influence of extracellular amino acids on the uptake and excretion of these two isomers in various organs.
  • Therefore, D-[(18)F]FMT would be a more powerful tool as a tumor-detecting agent for PET, especially for the imaging of a brain cancer and an abdominal cancer.
  • [MeSH-minor] Animals. Biological Transport. Cell Line, Tumor. Humans. Male. Mice. Mice, Inbred BALB C. Positron-Emission Tomography. Radioactive Tracers. Rats. Rats, Inbred F344. Staining and Labeling. Stereoisomerism

  • Hazardous Substances Data Bank. L-TYROSINE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19324275.001).
  • [ISSN] 1872-9614
  • [Journal-full-title] Nuclear medicine and biology
  • [ISO-abbreviation] Nucl. Med. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / O-(18F)fluoromethyl-L-tyrosine; 0 / Radioactive Tracers; 42HK56048U / Tyrosine
  •  go-up   go-down


82. Choi SJ, Oh JM, Choy JH: Toxicological effects of inorganic nanoparticles on human lung cancer A549 cells. J Inorg Biochem; 2009 Mar;103(3):463-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Toxicological effects of inorganic nanoparticles on human lung cancer A549 cells.
  • Many researches have shown that anionic clays can be used as delivery carriers for drug or gene molecules due to their efficient cellular uptake in vitro, and enhanced permeability and retention effect in vivo.
  • The toxicity of anionic clay, layered metal hydroxide nanoparticle, was evaluated in two human lung epithelial cells, carcinoma A549 cells and normal L-132 cells, and compared with that in other human cancer cell lines such as cervical adenocarcinoma cells (HeLa) and osteosarcoma cells (HOS).
  • However, exposing cancer cells to high concentrations (250-500 microg/ml) for 72 h resulted in an inflammatory response with oxidative stress and membrane damage, which varied with the cell type (A549>HOS>HeLa).
  • On the other hand, the toxicity mechanism seems to be different from that of other inorganic nanoparticles frequently studied for biological and medicinal applications such as iron oxide, silica, and single walled carbon nanotubes.
  • Silica triggered an inflammation response without causing considerable cell death for both cancer cells and normal cells, whereas layered metal hydroxide nanoparticle did not show any cytotoxic effects on normal L-132 cells in terms of inflammation response, oxidative stress, and membrane damage at the concentration of less than 250 microg/ml.
  • It is , therefore, highly expected that the present nanoparticle can be used as a efficient vehicle for drug delivery and cancer cell targeting as well.
  • [MeSH-major] Aluminum Silicates / toxicity. Cell Proliferation / drug effects. Drug Delivery Systems. Lung Neoplasms / drug therapy. Nanoparticles / toxicity
  • [MeSH-minor] Apoptosis / drug effects. Cell Line. Cell Survival / drug effects. Epithelial Cells / cytology. Epithelial Cells / drug effects. Epithelial Cells / metabolism. Humans. Interleukin-8 / metabolism. L-Lactate Dehydrogenase / metabolism. Microscopy, Electron, Scanning. Reactive Oxygen Species / analysis. Reactive Oxygen Species / metabolism

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19181388.001).
  • [ISSN] 1873-3344
  • [Journal-full-title] Journal of inorganic biochemistry
  • [ISO-abbreviation] J. Inorg. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aluminum Silicates; 0 / IL8 protein, human; 0 / Interleukin-8; 0 / Reactive Oxygen Species; 1302-87-0 / clay; EC 1.1.1.27 / L-Lactate Dehydrogenase
  •  go-up   go-down


83. Dabić MM, Nola M, Tomicić I, Dotlić S, Petrovecki M, Jukić S: Adenocarcinoma of the uterine cervix: prognostic significance of clinicopathologic parameters, flow cytometry analysis and HPV infection. Acta Obstet Gynecol Scand; 2008;87(3):366-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma of the uterine cervix: prognostic significance of clinicopathologic parameters, flow cytometry analysis and HPV infection.
  • BACKGROUND: This study was designed to determine the possible impact of status of human papillomavirus (HPV) infection (no infection, single, multiple infections) on the survival of patients with cervical adenocarcinoma, to correlate the HPV status with other clinicopathologic parameters, and to examine clinical, histological and flow cytometric parameters as predictors of survival in cervical adenocarcinoma.
  • METHODS: The clinical data of 51 patients with adenocarcinoma of the cervix who were treated at the Department of Gynecology and Obstetrics, Zagreb University School of Medicine, from 1978 to 2004 were analysed: age at presentation, menstrual status, clinical stage, relapse, survival.
  • CONCLUSION: Clinical stage and architectural grade are significant predictors for survival of patients with cervical adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / virology. Papillomaviridae / growth & development. Papillomavirus Infections / complications. Uterine Cervical Neoplasms / pathology. Uterine Cervical Neoplasms / virology


84. Ratković Z, Juranić ZD, Stanojković T, Manojlović D, Vukićević RD, Radulović N, Joksović MD: Synthesis, characterization, electrochemical studies and antitumor activity of some new chalcone analogues containing ferrocenyl pyrazole moiety. Bioorg Chem; 2010 Feb;38(1):26-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The in vitro cytotoxic activity of all the synthesized compounds was studied against cervix adenocarcinoma HeLa, melanoma Fem-x and myelogenous leukemia K562 cell lines by the MTT method.
  • [MeSH-major] Antineoplastic Agents / chemical synthesis. Chalcone / analogs & derivatives. Ferrous Compounds / chemistry. Pyrazoles / chemistry
  • [MeSH-minor] Cell Line, Tumor. Drug Screening Assays, Antitumor. Electrochemical Techniques. HeLa Cells. Humans. K562 Cells. Magnetic Resonance Spectroscopy. Spectrophotometry, Infrared

  • Hazardous Substances Data Bank. FERROCENE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier Inc. All rights reserved.
  • (PMID = 19846191.001).
  • [ISSN] 1090-2120
  • [Journal-full-title] Bioorganic chemistry
  • [ISO-abbreviation] Bioorg. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Ferrous Compounds; 0 / Pyrazoles; 5S5A2Q39HX / Chalcone; U96PKG90JQ / ferrocene
  •  go-up   go-down


85. Luo A, Wang W, Sima N, Lu Y, Zhou J, Xu G, Yu H, Wang S, Ma D: Short hairpin RNA targeting c-FLIP sensitizes human cervical adenocarcinoma Hela cells to chemotherapy and radiotherapy. Cancer Lett; 2008 Nov 28;271(2):323-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Short hairpin RNA targeting c-FLIP sensitizes human cervical adenocarcinoma Hela cells to chemotherapy and radiotherapy.
  • The present study aims at determining the effects of c-FLIP targeted vector-based short hairpin RNA (shRNA) on cell growth and evaluating its modulation of responsiveness to drugs and radiotherapy in cervical adenocarcinoma Hela cells. cFLIP expression of the cells transfected with shRNA against c-FLIP was significantly down-regulated after 72 h. c-FLIP silencing markedly suppressed cell proliferation and increased cell apoptosis.
  • Our data suggest that vector-based shRNA effectively inhibited c-FLIP expression, enhanced the expression level of caspase-8 and caspase-3 to induce cell apoptosis, probably with the higher efficacy in combination therapies with conventional chemotherapy and radiotherapy in cervical adenocarcinoma.
  • [MeSH-major] Antineoplastic Agents / pharmacology. CASP8 and FADD-Like Apoptosis Regulating Protein / genetics. RNA / genetics. Radiotherapy

  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18675507.001).
  • [ISSN] 1872-7980
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / CASP8 and FADD-Like Apoptosis Regulating Protein; 0 / CFLAR protein, human; 63231-63-0 / RNA; EC 3.4.22.- / Caspase 8
  •  go-up   go-down


86. Levgur M: Estrogen and combined hormone therapy for women after genital malignancies: a review. J Reprod Med; 2004 Oct;49(10):837-48
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This review summarizes information regarding estrogen therapy (ET) and hormone therapy (HT) for women with endometrial cancer as well as other gynecologic malignancies.
  • As to ovarian cancer, the information on hormone employment is scantier and derives mainly from statistical analysis of data on healthy users of estrogen alone or combined with progestin.
  • Several age-matched, case-control studies and 4 meta-analyses disclosed a higher rate, though not significant, of the later development of ovarian cancer among hormone users.
  • It is agreed, however, that the histologic type of the tumor is an important factor to consider prior to the initiation of such therapy.
  • The current literature permits ET in most cases of ovarian cancer, but further studies are needed to clearly delineate specific contraindications.
  • Utilizing estrogen compounds has no bearing on risks of later developing squamous cell carcinoma of the cervix, or tubal, vulvar or vaginal cancer.
  • A previous history of cervical adenocarcinoma, however, definitely prohibits the use of these hormonal regimens.
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Adult. Age Factors. Aged. Aged, 80 and over. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / pathology. Case-Control Studies. Continuity of Patient Care. Drug Therapy, Combination. Estrogen Replacement Therapy / adverse effects. Estrogen Replacement Therapy / methods. Female. Humans. Incidence. Middle Aged. Prognosis. Risk Assessment. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Hormone Replacement Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15568410.001).
  • [ISSN] 0024-7758
  • [Journal-full-title] The Journal of reproductive medicine
  • [ISO-abbreviation] J Reprod Med
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 75
  •  go-up   go-down


87. Xu Y, Ge R, Du J, Xin H, Yi T, Sheng J, Wang Y, Ling C: Corosolic acid induces apoptosis through mitochondrial pathway and caspase activation in human cervix adenocarcinoma HeLa cells. Cancer Lett; 2009 Nov 1;284(2):229-37
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Corosolic acid induces apoptosis through mitochondrial pathway and caspase activation in human cervix adenocarcinoma HeLa cells.
  • We investigated the response of human cervix adenocarcinoma HeLa cells to Corosolic acid (CRA) treatment.
  • Taken together, we believe that CRA could have strong potentials for clinical application in treating human cervix adenocarcinoma and improving cancer chemotherapy.
  • [MeSH-major] Adenocarcinoma / pathology. Antineoplastic Agents, Phytogenic / pharmacology. Caspases / physiology. Mitochondria / drug effects. Neoplasm Proteins / physiology. Triterpenes / pharmacology. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Actinidia / chemistry. Drug Screening Assays, Antitumor. Drugs, Chinese Herbal / chemistry. Enzyme Activation / drug effects. Female. HeLa Cells. Humans. Membrane Potential, Mitochondrial / drug effects. Molecular Structure. Proto-Oncogene Proteins c-bcl-2 / analysis. S Phase / drug effects. bcl-2-Associated X Protein / analysis

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2009 Elsevier Ireland Ltd.
  • (PMID = 19457606.001).
  • [ISSN] 1872-7980
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / BAX protein, human; 0 / Drugs, Chinese Herbal; 0 / Neoplasm Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Triterpenes; 0 / bcl-2-Associated X Protein; 4547-24-4 / corosolic acid; EC 3.4.22.- / Caspases
  •  go-up   go-down


88. Nijhuis ER, van der Zee AG, in 't Hout BA, Boomgaard JJ, de Hullu JA, Pras E, Hollema H, Aalders JG, Nijman HW, Willemse PH, Mourits MJ: Gynecologic examination and cervical biopsies after (chemo) radiation for cervical cancer to identify patients eligible for salvage surgery. Int J Radiat Oncol Biol Phys; 2006 Nov 1;66(3):699-705
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gynecologic examination and cervical biopsies after (chemo) radiation for cervical cancer to identify patients eligible for salvage surgery.
  • PURPOSE: The aim of this study was to evaluate efficacy of gynecologic examination under general anesthesia with cervical biopsies after (chemo) radiation for cervical cancer to identify patients with residual disease who may benefit from salvage surgery.
  • METHODS AND MATERIALS: In a retrospective cohort study data of all cervical cancer patients with the International Federation of Gynecology and Obstetrics (FIGO) Stage IB1 to IVA treated with (chemo) radiation between 1994 and 2001 were analyzed.
  • Cervical biopsy samples were taken from patients judged to be operable.
  • In case of residual cancer, salvage surgery was performed.
  • RESULTS: Between 1994 and 2001, 169 consecutive cervical cancer patients received primary (chemo) radiation, of whom 4 were lost to follow-up.
  • CONCLUSIONS: Gynecologic examination under anesthesia 8 to 10 weeks after (chemo) radiation with cervical biopsies allows identification of those cervical cancer patients who have residual local disease, of whom a small but significant proportion may be salvaged by surgery.
  • [MeSH-major] Cervix Uteri / pathology. Salvage Therapy. Uterine Cervical Neoplasms
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Adenocarcinoma / radiotherapy. Adenocarcinoma / surgery. Adult. Aged. Anesthesia, General. Biopsy. Carcinoma, Adenosquamous / drug therapy. Carcinoma, Adenosquamous / pathology. Carcinoma, Adenosquamous / radiotherapy. Carcinoma, Adenosquamous / surgery. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / radiotherapy. Carcinoma, Squamous Cell / surgery. Combined Modality Therapy / methods. Female. Follow-Up Studies. Humans. Middle Aged. Neoplasm, Residual. Retrospective Studies. Survival Analysis


89. Adamian RT: [Therapy of atypical hyperplasia and adenocarcinoma of the endometrium with the combination of progestins and anticoagulants]. Vopr Onkol; 2001;47(3):359-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Therapy of atypical hyperplasia and adenocarcinoma of the endometrium with the combination of progestins and anticoagulants].
  • The data on clinical trials of newly-developed hormonotherapy of atypical hyperplasia (AH) and cervical adenocarcinoma (CAC) are presented.
  • The study included 34 patients with histologically--confirmed AH and 86--CAC (stage I-II and III-IV).
  • It was found that hormonotherapy used in conjunction with anticoagulants reinforced significantly all features of hormonal pathomorphosism both in AH and CAC stage I-II while, in well-differentiated cell adenocarcinoma, the difference from control was significant (p < 0.05).
  • [MeSH-major] Adenocarcinoma / drug therapy. Anticoagulants / therapeutic use. Antineoplastic Agents, Hormonal / therapeutic use. Endometrial Neoplasms / drug therapy. Endometrium / pathology. Progesterone Congeners / therapeutic use
  • [MeSH-minor] Drug Therapy, Combination. Estrogen Antagonists / therapeutic use. Female. Humans. Hydroxyprogesterones / therapeutic use. Hyperplasia / drug therapy. Medroxyprogesterone Acetate / therapeutic use. Neoplasm Staging. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Blood Thinners.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11544839.001).
  • [ISSN] 0507-3758
  • [Journal-full-title] Voprosy onkologii
  • [ISO-abbreviation] Vopr Onkol
  • [Language] rus
  • [Publication-type] Clinical Trial; English Abstract; Journal Article; Randomized Controlled Trial
  • [Publication-country] Russia
  • [Chemical-registry-number] 0 / Anticoagulants; 0 / Antineoplastic Agents, Hormonal; 0 / Estrogen Antagonists; 0 / Hydroxyprogesterones; 0 / Progesterone Congeners; 276F2O42F5 / 17-alpha-hydroxy-progesterone caproate; C2QI4IOI2G / Medroxyprogesterone Acetate
  •  go-up   go-down


90. El-Awady RA, Ali MM, Saleh EM, Ghaleb FM: Apoptosis is the most efficient death-pathway in tumor cells after topoisomerase II inhibition. Saudi Med J; 2008 Apr;29(4):558-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: This study was carried out in the Tumor Biology Department, National Cancer Institute, Cairo University, Cairo, Egypt, from September 2005 to August 2007.
  • The breast cancer MCF7, the cervix carcinoma, human cervical adenocarcinoma Hela, and the brain tumor U251 cell lines were exposed to etoposide.
  • At equitoxic drug concentrations namely IC50, the Hela cells showed the lowest amount of non-repaired DNA dsb, and the MCF7's showed the highest amount, whereas the U251 cells showed a moderate amount.
  • CONCLUSION: These results indicate that although other modes of cell death exist, apoptosis is the most efficient and requires lower drug concentrations and fewer numbers of non-repaired dsb to give the same killing effect.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / pharmacology. Apoptosis. Cell Death. Cell Line, Tumor / drug effects. Etoposide / pharmacology. Topoisomerase II Inhibitors

  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18382799.001).
  • [ISSN] 0379-5284
  • [Journal-full-title] Saudi medical journal
  • [ISO-abbreviation] Saudi Med J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Saudi Arabia
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Topoisomerase II Inhibitors; 6PLQ3CP4P3 / Etoposide
  •  go-up   go-down


91. Vrdoljak E, Boraska Jelavic T, Saratlija-Novakovic Z, Hamm W: Concomitant chemobrachyradiotherapy with ifosfamide and cisplatin followed by consolidation chemotherapy in the treatment of locally advanced adenocarcinoma or adenosquamous carcinoma of the cervix uteri. Eur J Gynaecol Oncol; 2005;26(6):602-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concomitant chemobrachyradiotherapy with ifosfamide and cisplatin followed by consolidation chemotherapy in the treatment of locally advanced adenocarcinoma or adenosquamous carcinoma of the cervix uteri.
  • The optimal treatment of women with locally advanced adenocarcinoma or adenosquamous carcinoma of the cervix uteri is still undefined.
  • We report a series of four consecutive patients with locally advanced adeno- or adenosquamous carcinomas of the uterine cervix (FIGO Stages IB-IIIB) treated by concomitant chemobrachyradiotherapy with ifosfamide and cisplatin followed by one to four cycles of consolidation chemotherapy with the same drug combination.
  • Despite the low number of patients in this series we may conclude that concomitant chemobrachyradiotherapy with ifosfamide and cisplatin followed by consolidation chemotherapy with the same drug combination is an efficacious treatment of patients with locally advanced adeno- or adenosquamous carcinomas of the cervix uteri.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brachytherapy. Carcinoma, Adenosquamous / drug therapy. Uterine Cervical Neoplasms / drug therapy


92. Ajit D, Gavas S, Jagtap S, Chinoy RF: Cytodiagnostic problems in cervicovaginal smears from symptomatic breast cancer patients on tamoxifen therapy. Acta Cytol; 2009 Jul-Aug;53(4):383-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytodiagnostic problems in cervicovaginal smears from symptomatic breast cancer patients on tamoxifen therapy.
  • OBJECTIVE: To evaluate the effect of tamoxifen on cervicovaginal epithelium, identify tamoxifen-related changes that mimic cancer and detennine the morphologic features differentiating the 2 changes.
  • STUDY DESIGN: Cervicovaginal smears from 153 conventionally treated primary breast cancer patients presenting with gynecologic symptoms were studied.
  • Of 4 patients with a cytodiagnosis of atypical glandular changes, 2 had negative histology; 1 each had a uterine leiomyoma and endometrial hyperplasia.
  • Of the 6 cases reported as adenocarcinoma, 3 were histologically confirmed, and the others were false positives.
  • Tamoxifen-associated cellular changes can mimic morphologic features of cancer.
  • To avoid diagnostic errors, cervicovaginal smears should be repeated after discontinuing tamoxifen treatment.
  • [MeSH-major] Cervix Uteri / pathology. Tamoxifen / adverse effects. Uterine Cervical Neoplasms / pathology. Vagina / pathology. Vaginal Neoplasms / pathology. Vaginal Smears
  • [MeSH-minor] Adenocarcinoma / pathology. Adult. Aged. Antineoplastic Agents, Hormonal / adverse effects. Breast Neoplasms / drug therapy. Diagnosis, Differential. False Positive Reactions. Female. Humans. Middle Aged


93. De Luca T, Morré DM, Morré DJ: Reciprocal relationship between cytosolic NADH and ENOX2 inhibition triggers sphingolipid-induced apoptosis in HeLa cells. J Cell Biochem; 2010 Aug 15;110(6):1504-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ubiquitous in all cancer cell lines studied thus far, ENOX2 expression correlates with the abnormal growth and division associated with the malignant phenotype.
  • Here we present a possible mechanism that explains how these substances result in apoptosis in cancer cells by ENOX2-mediated alterations of cytosolic amounts of NAD(+) and NADH.
  • Their respective products sphingosine 1-phosphate (S1P) and ceramide (Cer) are key determinants of cell fate.
  • Using plasma membranes isolated from cervical adenocarcinoma (HeLa) cells as well as purified proteins of both bacterial and human origin, we demonstrate that NADH inhibits SK1 and stimulates nSMase, while NAD(+) inhibits nSMase and has no effect on SK1.
  • [MeSH-major] Apoptosis / drug effects. Catechin / analogs & derivatives. Isoflavones / pharmacology. Multienzyme Complexes / antagonists & inhibitors. NAD / metabolism. NADH, NADPH Oxidoreductases / antagonists & inhibitors
  • [MeSH-minor] Anticarcinogenic Agents / pharmacology. Cell Line. Cell Line, Tumor. Cell Membrane / drug effects. Cell Membrane / enzymology. Cell Membrane / metabolism. Cell Proliferation / drug effects. Cell Survival / drug effects. Ceramides / metabolism. Chromatography, Thin Layer. Cytosol / drug effects. Cytosol / metabolism. Dose-Response Relationship, Drug. HeLa Cells. Humans. Lysophospholipids / metabolism. Phosphotransferases (Alcohol Group Acceptor) / metabolism. Sphingolipids / metabolism. Sphingomyelin Phosphodiesterase / metabolism. Sphingosine / analogs & derivatives. Sphingosine / metabolism

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 Wiley-Liss, Inc.
  • (PMID = 20518072.001).
  • [ISSN] 1097-4644
  • [Journal-full-title] Journal of cellular biochemistry
  • [ISO-abbreviation] J. Cell. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / Ceramides; 0 / Isoflavones; 0 / Lysophospholipids; 0 / Multienzyme Complexes; 0 / Sphingolipids; 0U46U6E8UK / NAD; 26993-30-6 / sphingosine 1-phosphate; 8R1V1STN48 / Catechin; 995FT1W541 / phenoxodiol; BQM438CTEL / epigallocatechin gallate; EC 1.6.- / NADH oxidase; EC 1.6.- / NADH, NADPH Oxidoreductases; EC 2.7.1.- / Phosphotransferases (Alcohol Group Acceptor); EC 2.7.1.- / sphingosine kinase; EC 3.1.4.12 / Sphingomyelin Phosphodiesterase; NGZ37HRE42 / Sphingosine
  •  go-up   go-down


94. Rosner M, Siegel N, Fuchs C, Slabina N, Dolznig H, Hengstschläger M: Efficient siRNA-mediated prolonged gene silencing in human amniotic fluid stem cells. Nat Protoc; 2010 Jun;5(6):1081-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Human amniotic fluid stem cells (hAFSCs) are a very promising new type of fetal stem cells with numerous applications for basic science and cell-based therapies.
  • We also show the successful use of this protocol in primary nontransformed nonimmortalized fibroblasts, cervical adenocarcinoma cells, transformed embryonic kidney cells, immortalized endometrial stromal cells and acute monocytic leukemia cells, suggesting a wide spectrum of applications in various cell types.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20539284.001).
  • [ISSN] 1750-2799
  • [Journal-full-title] Nature protocols
  • [ISO-abbreviation] Nat Protoc
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / RNA, Small Interfering
  •  go-up   go-down


95. Chung MJ, Chung CK, Jeong Y, Ham SS: Anticancer activity of subfractions containing pure compounds of Chaga mushroom (Inonotus obliquus) extract in human cancer cells and in Balbc/c mice bearing Sarcoma-180 cells. Nutr Res Pract; 2010 Jun;4(3):177-82
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anticancer activity of subfractions containing pure compounds of Chaga mushroom (Inonotus obliquus) extract in human cancer cells and in Balbc/c mice bearing Sarcoma-180 cells.
  • The Chaga mushroom (Inonotus obliquus) has been used in folk medicine to treat cancers.
  • To test this hypothesis, the growth inhibition of each subfraction isolated from I. obliquus on human carcinoma cell lines (lung carcinoma A-549 cells, stomach adenocarcinoma AGS cells, breast adenocarcinoma MCF-7 cells, and cervical adenocarcinoma HeLa cells) was tested in vitro.
  • All of the subfractions isolated from I. obliquus showed significant cytotoxic activity against the selected cancer cell lines in vitro.
  • Subfraction 1 was more active than subfraction 2 and subfraction 3 against the A549, AGS and MCF-7 cancer cell lines in vitro.
  • The results suggest that I. obliquus and its compounds in these subfractions isolated from I. obliquus could be used as natural anticancer ingredients in the food and/or pharmaceutical industry.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Ethnopharmacol. 1991 Feb;31(2):175-9 [2023426.001]
  • [Cites] Mycologia. 1966 Jan-Feb;58(1):80-90 [5905024.001]
  • [Cites] Biosci Biotechnol Biochem. 1998 Mar;62(3):575-7 [9571790.001]
  • [Cites] Cancer Res. 1999 Oct 1;59(19):4743-58 [10519377.001]
  • [Cites] Toxicol Appl Pharmacol. 2005 Jun 15;205(3):225-36 [15922008.001]
  • [Cites] Bioorg Med Chem. 2007 Jan 1;15(1):257-64 [17049251.001]
  • [Cites] Phytother Res. 2009 Dec;23(12):1784-9 [19367670.001]
  • [Cites] Science. 1960 Dec 23;132(3443):1897 [17733317.001]
  • [Cites] Mutat Res. 2009 Jan;672(1):55-9 [18992843.001]
  • [Cites] Anticancer Res. 2008 Sep-Oct;28(5A):2691-6 [19035296.001]
  • [Cites] J Ethnopharmacol. 2009 Jan 21;121(2):221-8 [19041933.001]
  • [Cites] Nutr Res. 2009 Feb;29(2):123-9 [19285603.001]
  • [Cites] Planta Med. 1984 Apr;50(2):197-8 [17340294.001]
  • (PMID = 20607061.001).
  • [ISSN] 2005-6168
  • [Journal-full-title] Nutrition research and practice
  • [ISO-abbreviation] Nutr Res Pract
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2895696
  • [Keywords] NOTNLM ; Antitumor / cancer / cancer cells / mouse tumor / mushroom
  •  go-up   go-down


96. Yuan YV, Walsh NA: Antioxidant and antiproliferative activities of extracts from a variety of edible seaweeds. Food Chem Toxicol; 2006 Jul;44(7):1144-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Dietary Laminaria and Porphyra sp. have been reported to reduce the risk of intestinal or mammary cancer in animal studies.
  • Thus, in the present study, we evaluated the effect of red alga, dulse (Palmaria palmata) and three kelp (Laminaria setchellii, Macrocystis integrifolia, Nereocystis leutkeana) extracts on human cervical adenocarcinoma cell line (HeLa cells) proliferation using the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) assay.
  • The antiproliferative efficacy of these algal extracts were positively correlated with the total polyphenol contents (p<0.05), suggesting a causal link related to extract content of kelp phlorotannins and dulse polyphenols including mycosporine-like amino acids and phenolic acids.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Antioxidants / pharmacology. Seaweed / chemistry
  • [MeSH-minor] Cell Proliferation / drug effects. Flavonoids / analysis. HeLa Cells. Humans. Oxidation-Reduction. Phenols / analysis. Polyphenols

  • MedlinePlus Health Information. consumer health - Antioxidants.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16554116.001).
  • [ISSN] 0278-6915
  • [Journal-full-title] Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association
  • [ISO-abbreviation] Food Chem. Toxicol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antioxidants; 0 / Flavonoids; 0 / Phenols; 0 / Polyphenols
  •  go-up   go-down


97. Horvat S, Mlinarić-Majerski K, Glavas-Obrovac L, Jakas A, Veljković J, Marczi S, Kragol G, Roscić M, Matković M, Milostić-Srb A: Tumor-cell-targeted methionine-enkephalin analogues containing unnatural amino acids: design, synthesis, and in vitro antitumor activity. J Med Chem; 2006 Jun 1;49(11):3136-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor-cell-targeted methionine-enkephalin analogues containing unnatural amino acids: design, synthesis, and in vitro antitumor activity.
  • A series of new peptides (8-25) containing different unnatural amino acids of the adamantane type (1-6), was synthesized.
  • Possible cytotoxic activity on human cervical adenocarcinoma (HeLa), larynx carcinoma (HEp-2), colon carcinomas (HT-29, Caco-2), poorly differentiated cells from lymph node metastasis of colon carcinoma (SW-620), mammary gland adenocarcinoma (MCF-7), and melanoma (HBL) cells were tested by the MTT assay.
  • Peptide analogues containing C(alpha alpha)-dialkylated glycine (Aaa1, 1) or C(alpha)-alkylated glycine (Aaa2, 2) amino acid residues showed antitumor activity against melanoma, larynx carcinoma, colon carcinomas, and colon metastasis cell lines in vitro.
  • The pentapeptide Tyr-(R,S)-Aaa2-Gly-Phe-Met (18) was the most effective analogue especially against the most antitumor drug-resistant cell lines HEp-2 and SW-620.
  • [MeSH-major] Adamantane / analogs & derivatives. Adamantane / chemical synthesis. Amino Acids / chemical synthesis. Antineoplastic Agents / chemical synthesis. Enkephalin, Methionine / analogs & derivatives. Enkephalin, Methionine / chemical synthesis. Oligopeptides / chemical synthesis
  • [MeSH-minor] Cell Line. Cell Line, Tumor. Drug Resistance, Neoplasm. Drug Screening Assays, Antitumor. Humans. Hydrophobic and Hydrophilic Interactions. Stereoisomerism. Structure-Activity Relationship

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16722632.001).
  • [ISSN] 0022-2623
  • [Journal-full-title] Journal of medicinal chemistry
  • [ISO-abbreviation] J. Med. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Amino Acids; 0 / Antineoplastic Agents; 0 / Oligopeptides; 0 / tyrosyl-(1-adamantyl)glycyl-glycyl-phenylalanyl-methionine; 58569-55-4 / Enkephalin, Methionine; PJY633525U / Adamantane
  •  go-up   go-down


98. Nola M, Tomicic I, Dotlic S, Morovic A, Petrovecki M, Jukic S: Adenocarcinoma of uterine cervix -- prognostic significance of clinicopathologic parameters. Croat Med J; 2005 Jun;46(3):397-403
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma of uterine cervix -- prognostic significance of clinicopathologic parameters.
  • AIM: To investigate prognostic significance of several clinicopathologic parameters in patients with adenocarcinoma of the uterine cervix.
  • METHODS: We retrospectively studied 36 patients treated at the Department of Gynecology and Obstetrics, Zagreb University School of Medicine, Croatia, in the period from 1978-1998.
  • CONCLUSION: Our data showed that in patients with adenocarcinoma of the uterine cervix the nuclear grade, clinical stage, and architectural grade of the tumor represent the most important prognostic parameters.
  • [MeSH-major] Adenocarcinoma / mortality. Uterine Cervical Neoplasms / mortality


99. Lange TS, Kim KK, Singh RK, Strongin RM, McCourt CK, Brard L: Iron(III)-salophene: an organometallic compound with selective cytotoxic and anti-proliferative properties in platinum-resistant ovarian cancer cells. PLoS One; 2008 May 28;3(5):e2303
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Iron(III)-salophene: an organometallic compound with selective cytotoxic and anti-proliferative properties in platinum-resistant ovarian cancer cells.
  • BACKGROUND: In this pioneer study to the biological activity of organometallic compound Iron(III)-salophene (Fe-SP) the specific effects of Fe-SP on viability, morphology, proliferation, and cell-cycle progression on platinum-resistant ovarian cancer cell lines were investigated.
  • METHODOLOGY/PRINCIPAL FINDINGS: Fe-SP displayed selective cytotoxicity against SKOV-3 and OVCAR-3 (ovarian epithelial adenocarcinoma) cell lines at concentrations between 100 nM and 1 microM, while the viability of HeLa cells (epithelial cervix adenocarcinoma) or primary lung or skin fibroblasts was not affected.
  • Fe-SP exerted effects as an anti-proliferative agent with an IC(50) value of 300 nM and caused delayed progression of cells through S-phase phase of the cell cycle resulting in a complete S-phase arrest.
  • When intra-peritoneally applied to rats Fe-SP did not show any systemic toxicity at concentrations that in preliminary trials were determined to be chemotherapeutic relevant doses in a rat ovarian cancer cell model.
  • CONCLUSION/SIGNIFICANCE: The present report suggests that Fe-SP is a potent growth-suppressing agent in vitro for cell lines derived from ovarian cancer and a potential therapeutic drug to treat such tumors in vivo.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. PLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 1998 Aug 28;281(5381):1312-6 [9721091.001]
  • [Cites] J Biol Chem. 1998 Dec 11;273(50):33533-9 [9837934.001]
  • [Cites] Leukemia. 1999 Jul;13(7):1037-45 [10400419.001]
  • [Cites] Nat Cell Biol. 1999 Jul;1(3):E73-9 [10559915.001]
  • [Cites] J Clin Invest. 1999 Dec;104(12):1645-53 [10606615.001]
  • [Cites] Nucleic Acids Res. 1999 Nov 1;27(21):4160-6 [10518606.001]
  • [Cites] J Med Chem. 2004 Nov 18;47(24):5837-46 [15537341.001]
  • [Cites] Free Radic Biol Med. 2005 Jan 1;38(1):58-69 [15589372.001]
  • [Cites] Biochem Pharmacol. 2005 Apr 1;69(7):1009-39 [15763539.001]
  • [Cites] J Inorg Biochem. 2005 Jul;99(7):1433-40 [15878622.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jun 27;103(26):9756-60 [16785432.001]
  • [Cites] Arch Pharm (Weinheim). 2007 Mar;340(3):117-26 [17315259.001]
  • [Cites] Biochem Pharmacol. 2007 Jun 30;74(1):118-30 [17475222.001]
  • [Cites] Bioorg Med Chem Lett. 2007 Jul 1;17(13):3774-7 [17466518.001]
  • [Cites] Chem Biol Drug Des. 2007 Oct;70(4):302-10 [17937776.001]
  • [Cites] Genes Dev. 2007 Nov 15;21(22):2908-22 [18006686.001]
  • [Cites] J Inorg Biochem. 2008 Apr;102(4):740-7 [18180039.001]
  • [Cites] Gynecol Oncol. 2008 May;109(2):240-9 [18329084.001]
  • [Cites] Endocr Rev. 2001 Apr;22(2):153-83 [11294822.001]
  • [Cites] J Cell Biol. 2002 Apr 29;157(3):441-53 [11980919.001]
  • [Cites] Crit Rev Oncol Hematol. 2002 Jun;42(3):213-5 [12050015.001]
  • [Cites] J Med Chem. 2002 Sep 26;45(20):4549-58 [12238934.001]
  • [Cites] Cancer Cell. 2003 Sep;4(3):160-2 [14522248.001]
  • [Cites] Curr Cancer Drug Targets. 2004 Feb;4(1):65-75 [14965268.001]
  • [Cites] Oncogene. 2004 Apr 12;23(16):2774-84 [15077141.001]
  • [Cites] Int J Gynecol Cancer. 2004 Sep-Oct;14(5):772-8 [15361183.001]
  • [Cites] Arch Biochem Biophys. 1994 Nov 15;315(1):74-81 [7979408.001]
  • [Cites] Eur J Clin Pharmacol. 1994;47(1):1-16 [7988618.001]
  • [Cites] Science. 1994 Dec 16;266(5192):1821-8 [7997877.001]
  • [Cites] Curr Opin Cell Biol. 1995 Jun;7(3):337-43 [7662363.001]
  • [Cites] Bioorg Med Chem. 1996 Aug;4(8):1185-96 [8879539.001]
  • [Cites] Science. 1996 Dec 6;274(5293):1659-64 [8939847.001]
  • [Cites] Bioconjug Chem. 1997 Nov-Dec;8(6):789-92 [9404650.001]
  • [Cites] Bioconjug Chem. 1997 Nov-Dec;8(6):798-812 [9404652.001]
  • [Cites] Toxicology. 1997 Dec 31;124(3):179-92 [9482120.001]
  • [ErratumIn] PLoS ONE. 2008;3(7). doi: 10.1371/annotation/d97d24fc-aa07-40fd-88b2-6b2e050ddb31
  • (PMID = 18509533.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] ENG
  • [Grant] United States / NICHD NIH HHS / HD / K12 HD043447; United States / NCRR NIH HHS / RR / P20 RR018728; United States / NCRR NIH HHS / RR / 1-P20RR018728
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Ferric Compounds; 0 / Iron(III)-salophene; 49DFR088MY / Platinum
  • [Other-IDs] NLM/ PMC2386551
  •  go-up   go-down


100. Cheeti S, Lee CH: The involvement of intracellular calcium in the MCT-mediated uptake of lactic acid by HeLa cells. Mol Pharm; 2010 Feb 1;7(1):169-76
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The main object of this study was to evaluate the role of intracellular free calcium ion [Ca2+](in) in monocarboxylate transporter (MCT) mediated drug uptake by HeLa cells.
  • The changes in intracellular pH (pH(in)) and MCT mediated uptake rates of L-lactic acid by HeLa cells, a human cervical adenocarcinoma cell line, were evaluated under the conditions, whose [Ca2+](in) concentrations were altered by various calcium modulators, such as EGTA-AM (a chelator), nifedipine (a Ca2+ channel antagonist) and A23187 (an ionophore).
  • For the purpose of comparison, the L-lactic acid uptake by HeLa cells was also evaluated under various pH(in) conditions induced by dexamethasone.
  • The effects of the extracellular sodium concentration on the L-lactic acid uptake by HeLa cells were evaluated to determine the involvement of NHE-regulated pH changes in the MCT mediated drug uptake process.
  • An understanding of the role of [Ca2+](in) in the MCT mediated transport process could provide an efficient strategy to improve the systemic delivery of monocarboxylate substrates through the cervical mucosa.

  • Hazardous Substances Data Bank. Nifedipine .
  • Hazardous Substances Data Bank. LACTIC ACID .
  • Hazardous Substances Data Bank. SODIUM .
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Antimicrob Agents Chemother. 1992 Nov;36(11):2462-7 [1489189.001]
  • [Cites] Endocrinology. 1992 Sep;131(3):1125-33 [1324151.001]
  • [Cites] Biochim Biophys Acta. 1996 Jul 18;1275(1-2):127-32 [8688445.001]
  • [Cites] J Cell Sci. 1996 May;109 ( Pt 5):929-39 [8743940.001]
  • [Cites] Tohoku J Exp Med. 1996 Aug;179(4):291-4 [8944431.001]
  • [Cites] Biochem J. 1998 Jan 15;329 ( Pt 2):321-8 [9425115.001]
  • [Cites] J Am Coll Cardiol. 1999 Jan;33(1):242-9 [9935037.001]
  • [Cites] BJOG. 2005 Jun;112(6):754-8 [15924532.001]
  • [Cites] Int J Pharm. 2006 Nov 15;325(1-2):48-54 [16887304.001]
  • [Cites] Blood. 2007 May 1;109(9):3812-9 [17255361.001]
  • [Cites] Mol Cell Biochem. 2008 Mar;310(1-2):191-201 [18095144.001]
  • [Cites] BJU Int. 2008 Jun;101 Suppl 4:8-15 [18430116.001]
  • [Cites] J Nucl Med. 2008 Jun;49 Suppl 2:24S-42S [18523064.001]
  • [Cites] Crit Rev Ther Drug Carrier Syst. 2000;17(5):509-55 [11108158.001]
  • [Cites] Reprod Fertil Dev. 2000;12(3-4):201-7 [11302430.001]
  • [Cites] Am J Obstet Gynecol. 2001 Aug;185(2):375-9 [11518895.001]
  • [Cites] Antimicrob Agents Chemother. 2002 May;46(5):1375-80 [11959571.001]
  • [Cites] FEBS Lett. 2002 Jun 19;521(1-3):205-10 [12067706.001]
  • [Cites] Am J Physiol Cell Physiol. 2003 Dec;285(6):C1527-36 [12954600.001]
  • [Cites] Annu Rev Biochem. 1976;45:501-30 [786156.001]
  • [Cites] J Biol Chem. 1987 Jan 15;262(2):649-53 [3027061.001]
  • [Cites] Anal Biochem. 1987 Apr;162(1):156-9 [2440339.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Jan 1;89(1):123-7 [1309603.001]
  • [Cites] Biochem J. 1995 Nov 15;312 ( Pt 1):293-300 [7492327.001]
  • (PMID = 19905008.001).
  • [ISSN] 1543-8392
  • [Journal-full-title] Molecular pharmaceutics
  • [ISO-abbreviation] Mol. Pharm.
  • [Language] ENG
  • [Grant] United States / NICHD NIH HHS / HD / HD040784-01; United States / NICHD NIH HHS / HD / R15 HD040784; United States / NICHD NIH HHS / HD / HD 40784-01; United States / NICHD NIH HHS / HD / R15 HD040784-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Calcium Channel Blockers; 0 / Chelating Agents; 0 / DNA Primers; 0 / Ionophores; 0 / Monocarboxylic Acid Transporters; 0 / RNA, Messenger; 0 / Sodium-Hydrogen Antiporter; 0 / Symporters; 0 / monocarboxylate transport protein 1; 33X04XA5AT / Lactic Acid; 37H9VM9WZL / Calcimycin; 526U7A2651 / Egtazic Acid; 99590-86-0 / EGTA acetoxymethyl ester; 9NEZ333N27 / Sodium; I9ZF7L6G2L / Nifedipine; SY7Q814VUP / Calcium
  • [Other-IDs] NLM/ NIHMS159719; NLM/ PMC2815175
  •  go-up   go-down






Advertisement